<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006591</article-id><article-id pub-id-type="pmc">PMC11859843</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020224</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00224</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Fundamental and Targeted Approaches in Pulmonary Arterial Hypertension Treatment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Park</surname><given-names>Ji Su</given-names></name><xref rid="af1-pharmaceutics-17-00224" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-00224" ref-type="aff">2</xref><xref rid="fn1-pharmaceutics-17-00224" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Yong Hwan</given-names></name><xref rid="af1-pharmaceutics-17-00224" ref-type="aff">1</xref><xref rid="fn1-pharmaceutics-17-00224" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Min</surname><given-names>Ji-Young</given-names></name><xref rid="af1-pharmaceutics-17-00224" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jaeseong</given-names></name><xref rid="af1-pharmaceutics-17-00224" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2481-2436</contrib-id><name><surname>Shim</surname><given-names>Gayong</given-names></name><xref rid="af1-pharmaceutics-17-00224" ref-type="aff">1</xref><xref rid="af2-pharmaceutics-17-00224" ref-type="aff">2</xref><xref rid="c1-pharmaceutics-17-00224" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Moretton</surname><given-names>Marcela Analia</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Calienni</surname><given-names>Maria Natalia</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00224"><label>1</label>School of Systems Biomedical Science, Soongsil University, Seoul 06978, Republic of Korea; <email>jisu6042@soongsil.ac.kr</email> (J.S.P.); <email>iphone20011@soongsil.ac.kr</email> (Y.H.C.); <email>jymin0305@soongsil.ac.kr</email> (J.-Y.M.); <email>jsg@soongsil.ac.kr</email> (J.L.)</aff><aff id="af2-pharmaceutics-17-00224"><label>2</label>Integrative Institute of Basic Sciences, Soongsil University, Seoul 06978, Republic of Korea</aff><author-notes><corresp id="c1-pharmaceutics-17-00224"><label>*</label>Correspondence: <email>shim@ssu.ac.kr</email>; Tel.: +82-2-820-0451</corresp><fn id="fn1-pharmaceutics-17-00224"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>10</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>224</elocation-id><history><date date-type="received"><day>31</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>27</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>05</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Pulmonary arterial hypertension (PAH) is a chronic and progressive disease marked by vascular remodeling, inflammation, and smooth muscle cell proliferation, with limited treatment options focused primarily on symptom management. The multifactorial nature of PAH, encompassing genetic, autoimmune, and connective tissue contributions, complicates its treatment, while irreversible vascular changes, such as fibrosis, remain unaddressed by current therapies. Fundamental research on molecular pathways and targeted delivery systems has paved the way for advanced therapeutic strategies that aim to modify disease progression rather than merely manage symptoms. Nanoparticle-based drug delivery systems, leveraging controlled release and pulmonary targeting, offer a promising avenue to overcome these challenges. Such systems enable precise localization to pulmonary vasculature, minimize systemic side effects, and support emerging approaches like gene therapy and combination treatments. Future research should focus on refining nanoparticle formulations for personalized medicine, optimizing inhalation delivery systems, and integrating multi-target approaches to achieve curative outcomes in PAH. This review explores pathophysiology of PAH, current pharmacological strategies, and innovative nanoparticle-based therapies, emphasizing their potential to transform PAH treatment and address its underlying mechanisms.</p></abstract><kwd-group><kwd>pulmonary arterial hypertension</kwd><kwd>fundamental therapy</kwd><kwd>targeted therapy</kwd><kwd>nanoparticle-based drug delivery systems</kwd><kwd>pulmonary delivery systems</kwd></kwd-group><funding-group><award-group><funding-source>Institute of Civil Military Technology Cooperation</funding-source><award-id>22-CM-17</award-id></award-group><award-group><funding-source>Basic Science Research Program through the National Research Foundation of Korea</funding-source><award-id>2021R1A6A1A10044154</award-id></award-group><funding-statement>This research was financially supported by the Institute of Civil Military Technology Cooperation funded by the Defense Acquisition Program Administration and Ministry of Trade, Industry and Energy of Korean government under grant No. 22-CM-17 and the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (2021R1A6A1A10044154).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00224"><title>1. Introduction</title><p>Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized by elevated pulmonary arterial pressure due to vascular remodeling, inflammation, and smooth muscle cell proliferation [<xref rid="B1-pharmaceutics-17-00224" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-17-00224" ref-type="bibr">2</xref>]. Despite advancements in understanding the molecular and cellular mechanisms of PAH, current therapies focus primarily on symptom relief and slowing disease progression, failing to provide a definitive cure. PAH arises from a combination of factors, including autoimmune disorders, genetic predispositions, and connective tissue diseases, which makes it challenging for any single therapy to address the root causes. Furthermore, the disease is marked by irreversible structural changes in the pulmonary vasculature, such as vascular remodeling, thickening, and fibrosis, which current pharmacological options cannot reverse. This multifactorial pathophysiology and the limited scope of available treatments underscore the significant clinical challenges posed by PAH.</p><p>Fundamental treatment of PAH requires innovative therapeutic options, including gene therapies. Nucleic acid-based drugs, such as siRNA, miRNA, or mRNA, hold promise for correcting genetic abnormalities underlying the disease. However, these therapies are inherently unstable, with short half-lives, necessitating targeted delivery systems to ensure efficacy [<xref rid="B3-pharmaceutics-17-00224" ref-type="bibr">3</xref>]. Additionally, PAH often arises from diverse pathological factors, requiring the simultaneous targeting of multiple mechanisms. Combination therapies, leveraging either multi-drug loading on a single nanoparticle platform or the concurrent use of multiple nanoparticle systems, provide a versatile strategy to address these complex etiologies effectively [<xref rid="B4-pharmaceutics-17-00224" ref-type="bibr">4</xref>].</p><p>For the successful application of nanomedicine in PAH treatment, efficient pulmonary drug delivery is paramount. The lungs, with their extensive surface area and rich blood supply, represent an ideal route for drug administration. However, challenges such as inadequate drug accumulation in target sites or rapid systemic absorption often lead to suboptimal therapeutic outcomes and systemic side effects. Non-invasive approaches like inhalation or intratracheal injection allow for localized drug action while minimizing systemic exposure. Pulmonary-targeted strategies employing nanoparticles can enhance drug stability, control release kinetics, and enable selective accumulation at the target site, overcoming many limitations of current PAH therapies.</p><p>This review explores the pathophysiology of PAH, the pharmacological mechanisms of existing treatments, and the potential of nanoparticle-based drug delivery systems to revolutionize PAH management (<xref rid="pharmaceutics-17-00224-f001" ref-type="fig">Figure 1</xref>). Furthermore, it highlights pulmonary-targeted drug delivery strategies and innovative therapeutic developments, providing insights into a new paradigm for PAH treatment.</p></sec><sec id="sec2-pharmaceutics-17-00224"><title>2. Pathophysiology of PAH</title><p>Pulmonary hypertension (PH) is characterized by a mean pulmonary arterial pressure of at least 25 mmHg, primarily due to obstructive changes in the pulmonary vasculature [<xref rid="B5-pharmaceutics-17-00224" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-17-00224" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-17-00224" ref-type="bibr">7</xref>,<xref rid="B8-pharmaceutics-17-00224" ref-type="bibr">8</xref>]. PH is classified into five groups based on pathophysiological characteristics. Group 1, PAH, includes idiopathic and heritable forms and is often linked to connective tissue diseases and congenital heart defects [<xref rid="B9-pharmaceutics-17-00224" ref-type="bibr">9</xref>]. Group 2 results from left heart disease, such as left ventricular dysfunction, and valvular diseases like mitral valve disease [<xref rid="B10-pharmaceutics-17-00224" ref-type="bibr">10</xref>]. Group 3 is associated with lung diseases or hypoxia, commonly due to chronic obstructive pulmonary disease or interstitial lung disease [<xref rid="B11-pharmaceutics-17-00224" ref-type="bibr">11</xref>]. Group 4 involves pulmonary artery obstructions, primarily caused by chronic thromboembolic pulmonary disease [<xref rid="B12-pharmaceutics-17-00224" ref-type="bibr">12</xref>]. Group 5 includes cases with unclear or multifactorial mechanisms [<xref rid="B13-pharmaceutics-17-00224" ref-type="bibr">13</xref>]. PAH can develop due to various etiologies and typically progresses with symptoms such as dyspnea, fatigue, and right heart failure. Diagnosis involves transthoracic echocardiography and is confirmed through right heart catheterization [<xref rid="B9-pharmaceutics-17-00224" ref-type="bibr">9</xref>]. Delayed treatment increases mortality risk due to progressive pulmonary vascular remodeling and right ventricular failure.</p><p>The progression of PAH involves pulmonary vascular remodeling, characterized by intimal thickening, fibrosis, thrombotic lesions, and inflammatory cell infiltration. Key cellular contributors include pulmonary arterial endothelial cells and smooth muscle cells, which respond to inflammatory stimuli and oxidative stress, exacerbating disease progression [<xref rid="B14-pharmaceutics-17-00224" ref-type="bibr">14</xref>]. Genetic and environmental factors such as hypoxia, infections, and air pollutants contribute to the disease by promoting endothelial cell damage and vascular remodeling [<xref rid="B15-pharmaceutics-17-00224" ref-type="bibr">15</xref>,<xref rid="B16-pharmaceutics-17-00224" ref-type="bibr">16</xref>]. Genetic mutations in TGF-&#x003b2; superfamily proteins, such as BMPR2, ALK1, and ENG, play a significant role in heritable PAH by disrupting pulmonary vascular homeostasis [<xref rid="B17-pharmaceutics-17-00224" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-17-00224" ref-type="bibr">18</xref>]. Additional mutations, including KCNK3 and ATP13A3, contribute to vascular stiffening and endothelial dysfunction [<xref rid="B19-pharmaceutics-17-00224" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-17-00224" ref-type="bibr">20</xref>]. Chronic inflammation is another key factor driving PAH progression. Inflammatory cytokines, such as IL-6 and IL-1&#x003b2;, promote endothelial and smooth muscle cell proliferation and migration, contributing to vascular remodeling [<xref rid="B21-pharmaceutics-17-00224" ref-type="bibr">21</xref>]. Autoimmune diseases and genetic predispositions further exacerbate inflammatory responses, accelerating disease progression through increased cytokine expression and mitochondrial dysfunction [<xref rid="B22-pharmaceutics-17-00224" ref-type="bibr">22</xref>]. Understanding the interplay of these factors is essential for developing targeted therapeutic strategies to manage PAH effectively.</p></sec><sec id="sec3-pharmaceutics-17-00224"><title>3. Drug Classes and Mechanisms in PAH</title><p>The therapeutic goals for PAH include inducing vasodilation, suppressing inflammation and cellular proliferation, and alleviating vascular remodeling [<xref rid="B23-pharmaceutics-17-00224" ref-type="bibr">23</xref>]. Current pharmacological treatments for PAH primarily focus on managing symptoms, reducing pulmonary arterial pressure, and slowing disease progression rather than offering a definitive cure (<xref rid="pharmaceutics-17-00224-t001" ref-type="table">Table 1</xref>). These therapies address the complex pathology of the disease by targeting key mechanisms associated with vascular dysfunction.</p><sec id="sec3dot1-pharmaceutics-17-00224"><title>3.1. Conventional Approaches for PAH Management</title><p>PAH treatments currently used in clinical practice can be categorized into four main types: (i) endothelin receptor antagonists, (ii) phosphodiesterase type 5 inhibitors, (iii) drugs targeting the prostacyclin pathway, and (iv) soluble guanylate cyclase activators [<xref rid="B24-pharmaceutics-17-00224" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-17-00224" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-17-00224" ref-type="bibr">26</xref>].</p><sec id="sec3dot1dot1-pharmaceutics-17-00224"><title>3.1.1. Endothelin Receptor Antagonists</title><p>Endothelin acts as a potent blood vessel constrictor in lung tissue and is elevated in patients with PAH [<xref rid="B27-pharmaceutics-17-00224" ref-type="bibr">27</xref>]. Endothelin functions as both a pulmonary vasoconstrictor and a smooth muscle mitogen, leading to a reduction in pulmonary arterial lumen diameter and an increase in pulmonary arterial pressure, which can contribute to the development of PAH [<xref rid="B28-pharmaceutics-17-00224" ref-type="bibr">28</xref>]. Endothelin receptor antagonists block endothelin receptors, thereby inhibiting the progression of PAH caused by elevated endothelin levels. These antagonists are classified into two types: nonselective receptor antagonists (e.g., bosentan, macitentan), which block both endothelin A (ETA) and endothelin B (ETB) receptors, and selective receptor antagonists (e.g., ambrisentan), which block only the ETA receptor [<xref rid="B29-pharmaceutics-17-00224" ref-type="bibr">29</xref>,<xref rid="B30-pharmaceutics-17-00224" ref-type="bibr">30</xref>]. In PAH animal models, an imbalance in the expression of ETA and ETB receptors has been observed, with an initial upregulation of ETA receptors and a subsequent increase in ETB receptor expression in PASMCs, both of which have been implicated in PAH progression.</p></sec><sec id="sec3dot1dot2-pharmaceutics-17-00224"><title>3.1.2. Phosphodiesterase Type 5 Inhibitors</title><p>Phosphodiesterase type 5 (PDE5) degrades cyclic guanosine monophosphate (cGMP), thereby inhibiting the nitric oxide (NO)-mediated relaxation of smooth muscle and contributing to the development of PAH [<xref rid="B31-pharmaceutics-17-00224" ref-type="bibr">31</xref>,<xref rid="B32-pharmaceutics-17-00224" ref-type="bibr">32</xref>,<xref rid="B33-pharmaceutics-17-00224" ref-type="bibr">33</xref>,<xref rid="B34-pharmaceutics-17-00224" ref-type="bibr">34</xref>]. NO activates guanylate cyclase, increasing cGMP production, which promotes vasodilation of smooth muscle by upregulating K<sup>+</sup> channels, inhibiting Ca2<sup>+</sup> channels, and reducing intracellular Ca2<sup>+</sup> levels. In the PASMCs of PAH patients, PDE5 expression is upregulated, leading to enhanced cGMP degradation and excessive PASMC contraction. PDE5 inhibitors increase cGMP and NO levels, inducing PASMC relaxation and offering an effective therapeutic approach for PAH.</p><p>Sildenafil, an FDA-approved competitive inhibitor of cGMP-specific PDE5, enhances NO signaling, reducing pulmonary arterial pressure and promoting vasodilation, thereby alleviating PAH symptoms [<xref rid="B35-pharmaceutics-17-00224" ref-type="bibr">35</xref>]. Tadalafil, another FDA-approved PDE5 inhibitor for PAH treatment, effectively regulates smooth muscle contraction and promotes vasodilation in the pulmonary vasculature [<xref rid="B36-pharmaceutics-17-00224" ref-type="bibr">36</xref>]. Vardenafil, primarily used for erectile dysfunction, has demonstrated greater efficacy in PDE5 inhibition compared to sildenafil and tadalafil [<xref rid="B37-pharmaceutics-17-00224" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-17-00224" ref-type="bibr">38</xref>]. In monocrotaline (MCT)-induced PAH rat models, vardenafil reduced pulmonary artery pressure, alleviated vascular remodeling and right ventricular (RV) hypertrophy, inhibited PASMC proliferation, and mitigated oxidative stress [<xref rid="B37-pharmaceutics-17-00224" ref-type="bibr">37</xref>].</p></sec><sec id="sec3dot1dot3-pharmaceutics-17-00224"><title>3.1.3. Prostacyclin Pathway-Targeted Drugs</title><p>Prostacyclin (prostaglandin I2, PGI2) is synthesized in vascular endothelial cells and suppresses Ca<sup>2</sup>&#x0207a; influx, inducing vasodilation and inhibiting smooth muscle cell proliferation and platelet aggregation [<xref rid="B39-pharmaceutics-17-00224" ref-type="bibr">39</xref>]. Reduced prostacyclin levels lead to pulmonary endothelial dysfunction, a key contributor to PAH [<xref rid="B40-pharmaceutics-17-00224" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-17-00224" ref-type="bibr">41</xref>]. Beraprost, an orally administered prostacyclin analog, targets prostacyclin (IP) and prostaglandin E2 receptor subtype 3 (EP3). Studies in monocrotaline (MCT)-induced PAH rat models have demonstrated that beraprost effectively reduces pulmonary arterial remodeling and right ventricular (RV) hypertrophy [<xref rid="B42-pharmaceutics-17-00224" ref-type="bibr">42</xref>]. Iloprost, an FDA-approved inhaled prostacyclin analog, activates IP receptors and inhibits EP1, EP3, and EP4 activation, preventing vasoconstriction [<xref rid="B43-pharmaceutics-17-00224" ref-type="bibr">43</xref>]. Treprostinil palmitil, a prodrug designed for sustained release, overcomes the short half-life of treprostinil and exhibits enhanced efficacy in alleviating pulmonary vasoconstriction [<xref rid="B44-pharmaceutics-17-00224" ref-type="bibr">44</xref>].</p></sec><sec id="sec3dot1dot4-pharmaceutics-17-00224"><title>3.1.4. Soluble Guanylate Cyclase Activators</title><p>Soluble guanylate cyclase (sGC) is a key enzyme in the nitric oxide (NO)-cGMP signaling pathway that mediates smooth muscle relaxation and vasodilation. In PAH, endothelial dysfunction results in reduced NO bioavailability, leading to impaired sGC activation and decreased cGMP levels, which contribute to increased pulmonary arterial pressure and vascular remodeling [<xref rid="B45-pharmaceutics-17-00224" ref-type="bibr">45</xref>]. sGC activators, such as riociguat, directly stimulate sGC independently of NO, enhancing cGMP production and promoting vasodilation in pulmonary arteries. This mechanism bypasses NO deficiency and restores vascular homeostasis. Riociguat, an FDA-approved sGC activator, has demonstrated efficacy in reducing pulmonary arterial pressure and improving exercise capacity in PAH patients by enhancing endothelial function and reducing right ventricular afterload [<xref rid="B46-pharmaceutics-17-00224" ref-type="bibr">46</xref>].</p></sec></sec><sec id="sec3dot2-pharmaceutics-17-00224"><title>3.2. Current Pharmacological Approaches</title><p>Rho kinase inhibitors, such as fasudil, have emerged as promising therapeutic agents by targeting key pathological processes, including vascular contraction, PASMC proliferation, and endothelial dysfunction [<xref rid="B47-pharmaceutics-17-00224" ref-type="bibr">47</xref>]. Rho kinase plays a pivotal role in actin cytoskeleton organization and vasoconstriction, and its overactivation contributes to the increased vascular tone observed in PAH. Fasudil, delivered via liposomal inhalation, demonstrated sustained reductions in pulmonary arterial pressure in monocrotaline (MCT)-induced PAH rat models, effectively alleviating vascular remodeling without causing systemic vasodilation, thus minimizing adverse effects [<xref rid="B48-pharmaceutics-17-00224" ref-type="bibr">48</xref>].</p><p>Inflammation and oxidative stress are also critical contributors to PAH pathogenesis, as chronic inflammatory responses exacerbate endothelial injury and promote abnormal PASMC proliferation [<xref rid="B49-pharmaceutics-17-00224" ref-type="bibr">49</xref>]. Reactive oxygen species (ROS) generated in PAH patients impair endothelial cell function and enhance PASMC proliferation, accelerating vascular remodeling and disease progression.</p><p>To counteract oxidative stress, epigallocatechin gallate (EGCG), a natural antioxidant and anti-inflammatory agent, has shown potential in inhibiting TGF-&#x003b2; signaling pathways, thereby reducing PASMC proliferation and fibrosis [<xref rid="B50-pharmaceutics-17-00224" ref-type="bibr">50</xref>]. However, its clinical utility is limited by low stability and a short plasma half-life, prompting the development of liposomal inhalable formulations to enhance drug bioavailability and pulmonary retention.</p><p>Another promising antioxidant approach is ethyl pyruvate, which functions as both a ROS scavenger and a high-mobility group box 1 (HMGB1) inhibitor. Ethyl pyruvate has demonstrated attenuation of PAH progression in preclinical models by reducing inflammatory cytokine release and oxidative damage in pulmonary vasculature [<xref rid="B51-pharmaceutics-17-00224" ref-type="bibr">51</xref>].</p><p>Combination therapies, which integrate drugs with distinct mechanisms of action, are gaining attention for their synergistic effects in PAH treatment. For example, the co-administration of sildenafil and simvastatin has been shown to synergistically inhibit PASMC proliferation and vascular remodeling, offering an improved therapeutic outcome compared to monotherapy [<xref rid="B52-pharmaceutics-17-00224" ref-type="bibr">52</xref>]. Similarly, the combination of fasudil with superoxide dismutase (SOD) effectively mitigated PAH progression and right ventricular hypertrophy in preclinical models by targeting multiple pathological pathways concurrently [<xref rid="B47-pharmaceutics-17-00224" ref-type="bibr">47</xref>].</p></sec></sec><sec id="sec4-pharmaceutics-17-00224"><title>4. Targeted Strategies in PAH Treatment</title><p>Despite these advances, PAH treatments remain limited in their capacity to offer a cure, largely due to the complex and multifactorial nature of the disease. Research into fundamental treatments for PAH is ongoing, with emerging strategies focusing on direct targeting the mechanisms driving vascular remodeling and repair damaged vasculature. Promising agents such as sotatercept have shown potential in modulating vascular remodeling through pathways like bone morphogenetic protein (BMP) signaling, offering hope for more effective intervention. However, these therapies are still considered adjunctive rather than curative, emphasizing the need for continued innovation in PAH treatment. Current PAH therapies face significant limitations, including drug instability, short duration of action, nonspecific distribution, and formulation constraints. Moreover, many drugs effective against PAH exert systemic effects on the circulatory system, leading to dose limitations and heightened risks of adverse effects. These shortcomings underscore the need for advanced therapeutic strategies that can address the disease more precisely and effectively.</p><p>To overcome these obstacles, the development of nanoparticle-based drug delivery systems incorporating controlled-release technologies and targeted delivery strategies has garnered significant attention. PAH is considered a suitable candidate for such approaches due to its localized pathology within the pulmonary vasculature. Nanoparticles, composed of either naturally occurring or synthetically engineered materials, offer the ability to modulate drug release kinetics and preferentially accumulate drugs at target sites, thereby enhancing therapeutic efficacy while minimizing systemic side effects. This dual approach&#x02014;combining fundamental treatment development with pulmonary-targeted delivery&#x02014;represents a promising avenue for addressing the limitations of current PAH therapies and advancing toward curative solutions.</p><sec id="sec4dot1-pharmaceutics-17-00224"><title>4.1. Endothelin Receptor Antagonists</title><p>Bosentan (Bos) is a dual endothelin receptor antagonist (ETA and ETB) developed specifically for PAH treatment. Bosentan is poorly water-soluble, with its solubility highly dependent on pH [<xref rid="B53-pharmaceutics-17-00224" ref-type="bibr">53</xref>]. Drugs with solubility below 1 mg/mL at physiological pH often exhibit bioavailability issues [<xref rid="B42-pharmaceutics-17-00224" ref-type="bibr">42</xref>]. To address this, self-nanoemulsifying drug delivery systems (SNEDDS), which are isotropic mixtures of oil, surfactants, and co-surfactants, have been explored to improve Bosentan solubility and bioavailability [<xref rid="B53-pharmaceutics-17-00224" ref-type="bibr">53</xref>]. Compared to commercial formulations like Tracleer<sup>&#x000ae;</sup>, SNEDDS-loaded Bosentan demonstrated 3- to 8-fold higher dissolution rates in physiological media such as FaSSIF and FeSSIF. Another approach involves developing nanocomposites using Soluplus<sup>&#x000ae;</sup> polymers through single-emulsification and freeze-drying methods [<xref rid="B29-pharmaceutics-17-00224" ref-type="bibr">29</xref>]. These nanocomposites, with particle sizes below 100 nm, exhibited reduced crystallinity and improved amorphous stability over six months. Such strategies enhance bosentan solubility and bioavailability, offering a promising platform for PAH therapy.</p></sec><sec id="sec4dot2-pharmaceutics-17-00224"><title>4.2. PDE5 Inhibitors</title><p>Sildenafil (SD), a selective PDE5 inhibitor, prevents pulmonary arterial remodeling but suffers from poor pulmonary accumulation, a short half-life, and systemic side effects. To overcome these limitations, glucuronic acid (GlcA)-modified liposomes were developed to deliver SD specifically to PASMCs [<xref rid="B54-pharmaceutics-17-00224" ref-type="bibr">54</xref>]. These liposomes showed a 32.4% reduction in pulmonary arterial pressure (PAP), a 40% decrease in medial thickness, and a 45% improvement in right ventricular hypertrophy compared to free SD. Additionally, SD inhalation formulations have been investigated, including co-delivery systems using poly(lactic-co-glycolic acid) (PLGA) polymers [<xref rid="B54-pharmaceutics-17-00224" ref-type="bibr">54</xref>,<xref rid="B55-pharmaceutics-17-00224" ref-type="bibr">55</xref>]. In preclinical models, inhalable SD and rosiglitazone-loaded PLGA particles reduced mean PAP, mitigated pulmonary artery remodeling, and improved RV hypertrophy [<xref rid="B56-pharmaceutics-17-00224" ref-type="bibr">56</xref>]. Although the chronic safety of combination therapies needs further validation, these formulations offer a viable alternative for PAH treatment.</p></sec><sec id="sec4dot3-pharmaceutics-17-00224"><title>4.3. Prostacyclin Pathway-Targeted Drugs</title><p>Prostacyclin (PGI2) synthesis is impaired in PAH patients, contributing to vascular remodeling [<xref rid="B57-pharmaceutics-17-00224" ref-type="bibr">57</xref>]. While epoprostenol sodium infusion offers therapeutic benefits, it is associated with severe side effects like hypotension and catheter-related infections due to its short half-life. To address these issues, PLGA nanoparticles loaded with beraprost sodium have been developed, showing anti-proliferative and pro-apoptotic effects in PAH models [<xref rid="B58-pharmaceutics-17-00224" ref-type="bibr">58</xref>]. Liposomal inhaled iloprost has shown potent vasorelaxation effects in U-46619-induced PAH rat models [<xref rid="B43-pharmaceutics-17-00224" ref-type="bibr">43</xref>]. Treprostinil binds to IP and EP2 receptors, suppressing transforming growth factor-&#x003b2;1 (TGF-&#x003b2;1) and connective tissue growth factor expression, thereby reducing PASMC proliferation and migration [<xref rid="B59-pharmaceutics-17-00224" ref-type="bibr">59</xref>]. Treprostinil palmitil liposomal inhalation aerosols have also demonstrated extended pharmacokinetic profiles, with over 12 h of sustained activity, making them suitable for once-daily inhalation. Additionally, GlcA-modified liposomes loaded with treprostinil target GLUT-1 overexpression in PASMCs, leading to superior PAP reduction and sustained pulmonary accumulation [<xref rid="B59-pharmaceutics-17-00224" ref-type="bibr">59</xref>]. These innovations in prostacyclin delivery provide targeted and efficient PAH management.</p></sec><sec id="sec4dot4-pharmaceutics-17-00224"><title>4.4. Other Strategies</title><p>Fasudil, a rho kinase inhibitor, is formulated using PEGylated PLGA liposomes for inhalation therapy [<xref rid="B48-pharmaceutics-17-00224" ref-type="bibr">48</xref>]. These nanoparticles have reduced pulmonary arterial remodeling and sustained vascular dilation in PAH models. CAR-conjugated liposomes, targeting heparan sulfate, have also been developed to enhance specific pulmonary delivery, reducing off-target effects [<xref rid="B60-pharmaceutics-17-00224" ref-type="bibr">60</xref>]. CAR liposomes co-encapsulating fasudil and superoxide dismutase demonstrate prolonged drug release and improved anti-PAH efficacy [<xref rid="B61-pharmaceutics-17-00224" ref-type="bibr">61</xref>]. Additionally, bioinspired nanoerythrosome (NER)-based formulations have been used to encapsulate fasudil [<xref rid="B62-pharmaceutics-17-00224" ref-type="bibr">62</xref>]. Compared to intravenous bolus injections, CAR&#x02013;NER&#x02013;fasudil extended vasodilation effects from 60&#x02013;80 min to over 200 min and achieved a 1.5-fold greater reduction in mean PAP. These advanced formulations underscore the potential of nanotechnology in optimizing PAH therapies.</p></sec></sec><sec id="sec5-pharmaceutics-17-00224"><title>5. Pulmonary Targeting of Nanoparticle Systems for Disease Treatment</title><p>Pulmonary drug delivery is a form of drug targeting where therapeutic agents are delivered to the active site in the lungs for localized action or to absorption sites for systemic effects [<xref rid="B63-pharmaceutics-17-00224" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-17-00224" ref-type="bibr">64</xref>]. The former approach offers advantages such as relatively low doses, a low incidence of systemic side effects, and a rapid onset of action. Additionally, molecules designed to achieve systemic effects can also be delivered via the pulmonary route, circumventing low absorption rates through the gastrointestinal (GI) tract and avoiding the need for injectable formulations. The pulmonary epithelium, with its vast surface area of approximately 100 m<sup>2</sup> and its rich blood supply, is increasingly recognized as a promising non-invasive route for both localized and systemic drug delivery [<xref rid="B65-pharmaceutics-17-00224" ref-type="bibr">65</xref>]. This pathway is applicable not only to treating conditions like asthma, localized infections, and pulmonary hypertension but also for delivering systemic therapeutics such as insulin, human growth hormone, and oxytocin.</p><p>As important as drug mechanisms and development is the design of effective targeting systems. Precisely delivering drugs to specific organs minimizes undesired toxicity and maximizes therapeutic efficacy. The lung, as a respiratory organ, connects to the trachea via bronchi and is anatomically divided into the conducting zone (trachea, bronchi, and bronchioles) that transports air and the respiratory zone (alveoli and airways) responsible for gas exchange [<xref rid="B66-pharmaceutics-17-00224" ref-type="bibr">66</xref>]. The airway epithelium comprises the progressively thinning columnar epithelium, with the bronchial and bronchiolar layers measuring approximately 3.5 mm and 0.5&#x02013;1 mm in thickness, respectively. The lung contains over 300 million alveoli composed of type I and type II alveolar cells interspersed with an extensive capillary network [<xref rid="B67-pharmaceutics-17-00224" ref-type="bibr">67</xref>]. As oxygen moves from the alveoli to the bloodstream, it traverses a respiratory membrane approximately 0.5&#x02013;1.0 &#x003bc;m thick, consisting of alveolar and capillary walls. This structure also facilitates drug absorption. The high permeability of the respiratory membrane, extensive surface area, and sufficient blood flow prevent first-pass metabolism and enable drug accumulation in the lungs, making it ideal for treating pulmonary diseases [<xref rid="B68-pharmaceutics-17-00224" ref-type="bibr">68</xref>].</p><p>Therapeutic strategies for PAH using nanocarrier systems, where the majority of approaches employ intratracheal administration routes for enhanced efficacy, are summarized in <xref rid="pharmaceutics-17-00224-t002" ref-type="table">Table 2</xref>. In clinical settings, intratracheal injection is primarily utilized in preclinical animal studies and is rarely employed in human trials due to its inherent limitations. Instead, less invasive alternatives, such as inhalation delivery via nebulizers or inhalers, are widely adopted for pulmonary drug delivery, offering enhanced patient safety and convenience (<xref rid="pharmaceutics-17-00224-f002" ref-type="fig">Figure 2</xref>). In specific cases, intubation-assisted drug administration may be used, particularly in critical care settings, but its application remains limited. For intratracheal injection to gain broader clinical applicability, technological advancements ensuring minimal invasiveness and improved safety, such as nanocarrier-based drug formulations or precision catheter systems, would be essential.</p><p>Although pulmonary delivery has attracted considerable scientific interest over the past few decades, several challenges remain. For instance, therapeutic effects may dissipate quickly, necessitating frequent dosing (e.g., three to four times daily), and some drugs, such as bronchodilators, are rapidly absorbed through the pulmonary epithelium, leading to systemic side effects. However, recent advances in respiratory drug delivery strategies have led to significant improvements in delivery methods and devices. These advancements form the foundation for designing effective drug delivery systems tailored to pulmonary disease treatment.</p><sec id="sec5dot1-pharmaceutics-17-00224"><title>5.1. Pulmonary Drug Delivery Route</title><sec id="sec5dot1dot1-pharmaceutics-17-00224"><title>5.1.1. Inhalation</title><p>Inhalation is a non-invasive method of delivering drugs directly to the airway, maximizing therapeutic effects through high bronchial deposition and effective targeting [<xref rid="B94-pharmaceutics-17-00224" ref-type="bibr">94</xref>]. The success of inhalation therapy depends heavily on particle size, stability, and the choice of an appropriate inhaler, requiring formulations with optimized physicochemical properties [<xref rid="B95-pharmaceutics-17-00224" ref-type="bibr">95</xref>]. For effective inhalation, particle size must be &#x02264;5 &#x003bc;m to ensure deposition in the bronchioles and alveoli, with an aerodynamic size &#x02264;5 &#x003bc;m and high fine particle fraction (FPF), which considers particle density and shape for optimal lung deposition. In pulmonary arterial hypertension (PAH) treatments targeting the alveolar area, particles should be designed to be &#x02264;3 &#x003bc;m. Particles smaller than 1 &#x003bc;m can avoid mucociliary and alveolar macrophage clearance, enabling effective pulmonary deposition. Additionally, larger particles (&#x0003e;5 &#x003bc;m) pose a risk of deposition in the upper respiratory tract and potential systemic circulation through absorption, which raises safety concerns when administered intravenously.</p><p>Inhaled liposomes are preferred for pulmonary delivery due to their phospholipid composition, which mimics lung surfactants, allowing for effective drug localization in the lungs [<xref rid="B96-pharmaceutics-17-00224" ref-type="bibr">96</xref>]. They enable sustained drug release, improve stability and permeability, reduce systemic side effects, and enhance patient compliance. Studies and clinical trials on inhaled liposome formulations for treating various pulmonary diseases have been conducted [<xref rid="B97-pharmaceutics-17-00224" ref-type="bibr">97</xref>]. Although inhalable liposomal arikace for mycobacterial infection has received FDA approval, nanomedicine-based inhaled formulations for PAH treatment remain at the preclinical research stage.</p><p>Inhalation therapy employs three primary inhaler types: nebulizers, dry powder inhalers (DPIs), and pressurized metered-dose inhalers (pMDIs) [<xref rid="B98-pharmaceutics-17-00224" ref-type="bibr">98</xref>]. Nebulizers generate liquid aerosols without the need for propellants, enabling uniform drug delivery to deep lung tissues via respiration, making them a preferred dosage form [<xref rid="B99-pharmaceutics-17-00224" ref-type="bibr">99</xref>]. Research on liposome-based formulations delivered through nebulization has demonstrated high FPF (53.46%) and suitable MMAD (4.41 &#x003bc;m), enabling effective drug deposition in the alveolar region of PAH lungs [<xref rid="B50-pharmaceutics-17-00224" ref-type="bibr">50</xref>]. Vibrating mesh nebulization techniques minimize lipid bilayer damage, reducing drug loss and aggregation while improving delivery efficiency. Similar to liposomes, solid lipid nanoparticles (SLNs) or biodegradable and biocompatible PLGA (poly(lactic-co-glycolic acid)) nanoparticles can form respirable aerosols [<xref rid="B100-pharmaceutics-17-00224" ref-type="bibr">100</xref>]. These nanoparticles minimize lung tissue damage and enable effective pulmonary delivery via nebulizers. PLGA nanoparticles, with their porous structure and low density, allow for sustained drug release and efficient lung deposition [<xref rid="B74-pharmaceutics-17-00224" ref-type="bibr">74</xref>]. For drugs prone to aggregation and toxicity at high concentrations, nebulization provides uniform and targeted lung delivery, reducing toxicity and enhancing therapeutic outcomes [<xref rid="B101-pharmaceutics-17-00224" ref-type="bibr">101</xref>]. pMDIs use propellants to deliver aerosolized drugs to the lungs effectively [<xref rid="B94-pharmaceutics-17-00224" ref-type="bibr">94</xref>]. Liposome-based pMDI formulations enable sustained drug release, reduced systemic exposure, and improved therapeutic outcomes. Aerosolized liposome formulations with MMAD (1.54 &#x003bc;m) and FPF (74%) demonstrated effective lung targeting, reduced cough reflex, and improved patient compliance. DPIs deliver nanomedicine-based powders formulated using spray-drying techniques, ensuring drug stability and direct deposition into deep lung tissues [<xref rid="B99-pharmaceutics-17-00224" ref-type="bibr">99</xref>]. Formulations using excipients like mannitol exhibit respirable particle sizes (1&#x02013;5 &#x003bc;m) and high FPF, enabling sustained drug release and effective lung deposition [<xref rid="B102-pharmaceutics-17-00224" ref-type="bibr">102</xref>]. For hydrophobic drugs (e.g., simvastatin), DPIs are particularly useful, as the drugs dissolve in the lungs for immediate therapeutic effects [<xref rid="B31-pharmaceutics-17-00224" ref-type="bibr">31</xref>]. These formulations are easy to store and use without refrigeration or solubilization, although they pose challenges in dosage accuracy, drug wastage, and nasal cavity deposition. A dry powder formulation developed to enhance bioavailability and reduce systemic side effects showed a 13.7-fold increase in solubility compared to free tadalafil [<xref rid="B103-pharmaceutics-17-00224" ref-type="bibr">103</xref>]. Intratracheal insufflation demonstrated significant improvements in MRT (2.3-fold) and tmax (3.7-fold) compared to oral administration. Widely used as a bronchodilator for asthma treatment, SS encapsulated in liposome carriers and delivered via DPI exhibited sustained drug release (90% over 14 h) [<xref rid="B104-pharmaceutics-17-00224" ref-type="bibr">104</xref>].</p></sec><sec id="sec5dot1dot2-pharmaceutics-17-00224"><title>5.1.2. Intratracheal Injection</title><p>Intratracheal (IT) injection delivers drugs directly to the lungs with high precision and efficiency, requiring only small amounts. It minimizes nasal cavity deposition and systemic distribution, reducing side effects while ensuring effective lung deposition. IT injection is recognized as an effective delivery route for PAH and other pulmonary diseases. Administering aerosolized drugs via IT injection ensures uniform distribution and effective deposition in deep lung areas, maximizing therapeutic outcomes.</p><p>Studies using polymer-based aerosol nanoparticles have demonstrated successful drug delivery to lung tissues in PAH animal models, alleviating symptoms and slowing disease progression [<xref rid="B79-pharmaceutics-17-00224" ref-type="bibr">79</xref>]. Liposome and lipid nanoparticle (LNP)-based aerosols have improved bioavailability and sustained drug release, achieving high therapeutic efficacy through IT injection [<xref rid="B48-pharmaceutics-17-00224" ref-type="bibr">48</xref>,<xref rid="B105-pharmaceutics-17-00224" ref-type="bibr">105</xref>]. Ligand-modified nanoparticles designed for cell-specific delivery have also been extensively studied [<xref rid="B60-pharmaceutics-17-00224" ref-type="bibr">60</xref>,<xref rid="B73-pharmaceutics-17-00224" ref-type="bibr">73</xref>]. For example, CAR-modified liposomes target overexpressed heparan sulfate in PASMCs, selectively accumulating in proliferative SMCs of PAH lungs [<xref rid="B60-pharmaceutics-17-00224" ref-type="bibr">60</xref>]. When delivered via aerosolized IT injection, systemic entry was reduced and cellular uptake increased, enhancing therapeutic effects. While IT injection offers high delivery accuracy and low drug loss, it carries risks of lung tissue damage from repeated administration and requires anesthesia, limiting its use in some scenarios. Nevertheless, IT injection remains a promising strategy for pulmonary drug delivery.</p></sec></sec><sec id="sec5dot2-pharmaceutics-17-00224"><title>5.2. Non-Pulmonary Drug Delivery Route</title><sec id="sec5dot2dot1-pharmaceutics-17-00224"><title>5.2.1. Intravenous Injection</title><p>Intravenous (IV) injection is a common method for administering large volumes of drugs, avoiding first-pass metabolism and providing the potential for delivering drugs to the lungs [<xref rid="B106-pharmaceutics-17-00224" ref-type="bibr">106</xref>]. IV-administered particulate drug delivery systems are designed to selectively lodge in pulmonary capillaries, requiring particle sizes slightly larger than the capillary diameters, which are approximately 7.5 &#x000b1; 2.3 &#x003bc;m in healthy adults and 6.6 &#x000b1; 1.6 &#x003bc;m or 7.5 &#x000b1; 1.7 &#x003bc;m in rats and dogs, respectively. Many drugs are encapsulated in carriers such as microspheres, microcapsules, liposomes, and nanoparticles for delivery to the lungs via IV routes. These carriers regulate drug distribution and release, prolong drug action, and improve therapeutic efficacy and patient compliance. IV injection leverages increased vascular permeability in PAH to efficiently accumulate nanoparticles using passive targeting mechanisms. This approach mitigates the limitations of systemic drug distribution and enables lung-specific delivery through surface modifications of nanoparticles.</p><p>IV drug delivery strategies include the use of ligand-modified nanoparticles to selectively deliver drugs to lung tissues [<xref rid="B59-pharmaceutics-17-00224" ref-type="bibr">59</xref>]. Glucuronic acid (GlcA), a glucose analog, targets glucose transporter-1 (GLUT-1), which is overexpressed in PAH PASMCs, enhancing pulmonary drug distribution and cellular uptake. Such approaches have demonstrated selective accumulation of nanoparticles in pulmonary arteries and effective inhibition of vascular remodeling [<xref rid="B107-pharmaceutics-17-00224" ref-type="bibr">107</xref>]. Cell-penetrating peptides like octaarginine (R8) have been used to enhance lung accumulation of liposomes. Similarly, nanoparticles conjugated with E-selectin ligands exhibit high specificity for pulmonary vascular endothelium, achieving efficient delivery [<xref rid="B108-pharmaceutics-17-00224" ref-type="bibr">108</xref>]. Additionally, surface modifications with polymers such as polyethylene glycol (PEG) and polyethylenimine (PEI) improve lung targeting [<xref rid="B109-pharmaceutics-17-00224" ref-type="bibr">109</xref>]. PEG reduces opsonization and serum protein interactions, extending blood circulation time and enhancing nanoparticle stability. PEI provides a positive charge to nanoparticles, facilitating their interaction with the negatively charged lung endothelial glycocalyx and promoting cellular uptake.</p></sec><sec id="sec5dot2dot2-pharmaceutics-17-00224"><title>5.2.2. Intraperitoneal Injection</title><p>Intraperitoneal (IP) injection delivers drugs into systemic circulation, maintaining consistent drug concentrations and serving as an effective method for poorly soluble drugs [<xref rid="B76-pharmaceutics-17-00224" ref-type="bibr">76</xref>]. Emulsion-based drugs administered via IP injection have been shown to reduce migration and proliferation of PAH PASMCs [<xref rid="B110-pharmaceutics-17-00224" ref-type="bibr">110</xref>]. However, IP injection has been associated with systemic side effects, such as decreased systolic blood pressure and liver damage, making it less commonly used for PAH treatment [<xref rid="B76-pharmaceutics-17-00224" ref-type="bibr">76</xref>]. Research targeting lung tumors has utilized HA-PEI nanoparticles to deliver miR-125b to peritoneal macrophages [<xref rid="B111-pharmaceutics-17-00224" ref-type="bibr">111</xref>]. HA selectively binds to macrophages and directs them to inflammation sites, successfully targeting tumor-associated macrophages (TAMs) and achieving significant outcomes in cancer immunotherapy.</p></sec><sec id="sec5dot2dot3-pharmaceutics-17-00224"><title>5.2.3. Oral Administration</title><p>Oral administration is widely preferred due to its simplicity and high patient compliance [<xref rid="B53-pharmaceutics-17-00224" ref-type="bibr">53</xref>,<xref rid="B112-pharmaceutics-17-00224" ref-type="bibr">112</xref>]. However, it is limited by the gastrointestinal (GI) environment, which reduces drug stability, absorption rates, and bioactivity through first-pass metabolism [<xref rid="B53-pharmaceutics-17-00224" ref-type="bibr">53</xref>]. PAH treatments include oral drugs such as bosentan, tadalafil, ambrisentan, and sildenafil. While oral formulations offer longer plasma half-lives than subcutaneous, intravenous, or inhaled forms, they present challenges in managing adverse effects such as hypotension or pulmonary edema [<xref rid="B113-pharmaceutics-17-00224" ref-type="bibr">113</xref>].</p><p>Nanoparticle-based formulations have been developed to address these issues [<xref rid="B112-pharmaceutics-17-00224" ref-type="bibr">112</xref>]. Solid lipid nanoparticles (SLNs) with an average size of 130 nm exhibit rapid initial drug release followed by sustained release patterns, improving drug stability and therapeutic efficacy. Lipid core nanocapsules (LNCs) extend drug half-lives, enhance bioavailability, and effectively suppress PAH progression [<xref rid="B30-pharmaceutics-17-00224" ref-type="bibr">30</xref>]. Emulsion-based formulations further improve oral bioavailability and absorption of lipophilic drugs, such as ambrisentan, bosentan, and sildenafil, by bypassing first-pass metabolism and inhibiting P-glycoprotein-mediated drug efflux [<xref rid="B35-pharmaceutics-17-00224" ref-type="bibr">35</xref>,<xref rid="B53-pharmaceutics-17-00224" ref-type="bibr">53</xref>,<xref rid="B114-pharmaceutics-17-00224" ref-type="bibr">114</xref>].</p></sec></sec></sec><sec sec-type="conclusions" id="sec6-pharmaceutics-17-00224"><title>6. Conclusions</title><p>PAH remains a significant clinical challenge due to its complex pathophysiology and the limited efficacy of existing treatment options. Nanoparticle-based drug delivery systems for pulmonary targeting present a promising approach to address these challenges by offering precise drug localization, controlled release, and prolonged retention in the lungs, thereby minimizing systemic toxicity and enhancing patient compliance. Unlike conventional delivery methods that primarily focus on symptom management, nanoparticle-based strategies provide a means to directly interact with diseased pulmonary vasculature, facilitating targeted modulation of pathogenic pathways such as endothelial dysfunction, inflammation, and vascular remodeling.</p><p>Future research should focus on optimizing nanoparticle formulations in combination with advanced inhalation devices to ensure efficient pulmonary deposition and therapeutic efficacy. Additionally, the exploration of personalized medicine approaches, such as patient-specific nanoparticle formulations tailored to genetic profiles, may further enhance treatment outcomes. Ultimately, the integration of cutting-edge drug delivery technologies and molecular therapies offers a transformative opportunity to improve PAH management and enhance the quality of life for patients.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, G.S.; investigation, J.S.P., Y.H.C., J.-Y.M. and J.L.; writing&#x02014;original draft preparation, J.S.P. and Y.H.C.; Visualization, J.S.P.; writing&#x02014;review and editing, G.S.; supervision, G.S.; funding acquisition, G.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00224"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Montani</surname><given-names>D.</given-names></name>
<name><surname>G&#x000fc;nther</surname><given-names>S.</given-names></name>
<name><surname>Dorfm&#x000fc;ller</surname><given-names>P.</given-names></name>
<name><surname>Perros</surname><given-names>F.</given-names></name>
<name><surname>Girerd</surname><given-names>B.</given-names></name>
<name><surname>Garcia</surname><given-names>G.</given-names></name>
<name><surname>Ja&#x000ef;s</surname><given-names>X.</given-names></name>
<name><surname>Savale</surname><given-names>L.</given-names></name>
<name><surname>Artaud-Macari</surname><given-names>E.</given-names></name>
<name><surname>Price</surname><given-names>L.C.</given-names></name>
</person-group><article-title>Pulmonary arterial hypertension</article-title><source>Orphanet J. Rare Dis.</source><year>2013</year><volume>8</volume><fpage>97</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-8-97</pub-id><pub-id pub-id-type="pmid">23829793</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00224"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mubarak</surname><given-names>K.K.</given-names></name>
</person-group><article-title>A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension</article-title><source>Respir. Med.</source><year>2010</year><volume>104</volume><fpage>9</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.rmed.2009.07.015</pub-id><pub-id pub-id-type="pmid">19683911</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00224"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paunovska</surname><given-names>K.</given-names></name>
<name><surname>Loughrey</surname><given-names>D.</given-names></name>
<name><surname>Dahlman</surname><given-names>J.E.</given-names></name>
</person-group><article-title>Drug delivery systems for RNA therapeutics</article-title><source>Nat. Rev. Genet.</source><year>2022</year><volume>23</volume><fpage>265</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1038/s41576-021-00439-4</pub-id><pub-id pub-id-type="pmid">34983972</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00224"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakamura</surname><given-names>K.</given-names></name>
<name><surname>Matsubara</surname><given-names>H.</given-names></name>
<name><surname>Akagi</surname><given-names>S.</given-names></name>
<name><surname>Sarashina</surname><given-names>T.</given-names></name>
<name><surname>Ejiri</surname><given-names>K.</given-names></name>
<name><surname>Kawakita</surname><given-names>N.</given-names></name>
<name><surname>Yoshida</surname><given-names>M.</given-names></name>
<name><surname>Miyoshi</surname><given-names>T.</given-names></name>
<name><surname>Watanabe</surname><given-names>A.</given-names></name>
<name><surname>Nishii</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Nanoparticle-mediated drug delivery system for pulmonary arterial hypertension</article-title><source>J. Clin. Med.</source><year>2017</year><volume>6</volume><elocation-id>48</elocation-id><pub-id pub-id-type="doi">10.3390/jcm6050048</pub-id><pub-id pub-id-type="pmid">28468233</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00224"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sysol</surname><given-names>J.</given-names></name>
<name><surname>Machado</surname><given-names>R.</given-names></name>
</person-group><article-title>Classification and pathophysiology of pulmonary hypertension</article-title><source>Contin. Cardiol. Educ.</source><year>2018</year><volume>4</volume><fpage>2</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1002/cce2.71</pub-id></element-citation></ref><ref id="B6-pharmaceutics-17-00224"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Simonneau</surname><given-names>G.</given-names></name>
<name><surname>Montani</surname><given-names>D.</given-names></name>
<name><surname>Celermajer</surname><given-names>D.S.</given-names></name>
<name><surname>Denton</surname><given-names>C.P.</given-names></name>
<name><surname>Gatzoulis</surname><given-names>M.A.</given-names></name>
<name><surname>Krowka</surname><given-names>M.</given-names></name>
<name><surname>Williams</surname><given-names>P.G.</given-names></name>
<name><surname>Souza</surname><given-names>R.</given-names></name>
</person-group><article-title>Haemodynamic definitions and updated clinical classification of pulmonary hypertension</article-title><source>Eur. Respir. J.</source><year>2019</year><volume>53</volume><fpage>1801913</fpage><pub-id pub-id-type="doi">10.1183/13993003.01913-2018</pub-id><pub-id pub-id-type="pmid">30545968</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00224"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gali&#x000e8;</surname><given-names>N.</given-names></name>
<name><surname>Humbert</surname><given-names>M.</given-names></name>
<name><surname>Vachiery</surname><given-names>J.-L.</given-names></name>
<name><surname>Gibbs</surname><given-names>S.</given-names></name>
<name><surname>Lang</surname><given-names>I.</given-names></name>
<name><surname>Torbicki</surname><given-names>A.</given-names></name>
<name><surname>Simonneau</surname><given-names>G.</given-names></name>
<name><surname>Peacock</surname><given-names>A.</given-names></name>
<name><surname>Vonk Noordegraaf</surname><given-names>A.</given-names></name>
<name><surname>Beghetti</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)</article-title><source>Eur. Heart J.</source><year>2015</year><volume>37</volume><fpage>67</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehv317</pub-id><pub-id pub-id-type="pmid">26320113</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00224"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gelzinis</surname><given-names>T.A.</given-names></name>
</person-group><article-title>Pulmonary Hypertension in 2021: Part I&#x02014;Definition, Classification, Pathophysiology, and Presentation</article-title><source>J. Cardiothorac. Vasc. Anesth.</source><year>2022</year><volume>36</volume><fpage>1552</fpage><lpage>1564</lpage><pub-id pub-id-type="doi">10.1053/j.jvca.2021.06.036</pub-id><pub-id pub-id-type="pmid">34344595</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00224"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruopp</surname><given-names>N.F.</given-names></name>
<name><surname>Cockrill</surname><given-names>B.A.</given-names></name>
</person-group><article-title>Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review</article-title><source>Jama</source><year>2022</year><volume>327</volume><fpage>1379</fpage><lpage>1391</lpage><pub-id pub-id-type="doi">10.1001/jama.2022.4402</pub-id><pub-id pub-id-type="pmid">35412560</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00224"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fang</surname><given-names>J.C.</given-names></name>
<name><surname>DeMarco</surname><given-names>T.</given-names></name>
<name><surname>Givertz</surname><given-names>M.M.</given-names></name>
<name><surname>Borlaug</surname><given-names>B.A.</given-names></name>
<name><surname>Lewis</surname><given-names>G.D.</given-names></name>
<name><surname>Rame</surname><given-names>J.E.</given-names></name>
<name><surname>Gomberg-Maitland</surname><given-names>M.</given-names></name>
<name><surname>Murali</surname><given-names>S.</given-names></name>
<name><surname>Frantz</surname><given-names>R.P.</given-names></name>
<name><surname>McGlothlin</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>World Health Organization Pulmonary Hypertension Group 2: Pulmonary hypertension due to left heart disease in the adult&#x02014;A summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation</article-title><source>J. Heart Lung Transplant.</source><year>2012</year><volume>31</volume><fpage>913</fpage><lpage>933</lpage><pub-id pub-id-type="doi">10.1016/j.healun.2012.06.002</pub-id><pub-id pub-id-type="pmid">22884380</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00224"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>N.</given-names></name>
<name><surname>Dorfm&#x000fc;ller</surname><given-names>P.</given-names></name>
<name><surname>Shlobin</surname><given-names>O.A.</given-names></name>
<name><surname>Ventetuolo</surname><given-names>C.E.</given-names></name>
</person-group><article-title>Group 3 Pulmonary Hypertension: From Bench to Bedside</article-title><source>Circ. Res.</source><year>2022</year><volume>130</volume><fpage>1404</fpage><lpage>1422</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.319970</pub-id><pub-id pub-id-type="pmid">35482836</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00224"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>N.H.</given-names></name>
</person-group><article-title>Group 4 Pulmonary Hypertension: Chronic Thromboembolic Pulmonary Hypertension: Epidemiology, Pathophysiology, and Treatment</article-title><source>Cardiol. Clin.</source><year>2016</year><volume>34</volume><fpage>435</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1016/j.ccl.2016.04.011</pub-id><pub-id pub-id-type="pmid">27443139</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00224"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lahm</surname><given-names>T.</given-names></name>
<name><surname>Chakinala</surname><given-names>M.M.</given-names></name>
</person-group><article-title>World Health Organization group 5 pulmonary hypertension</article-title><source>Clin. Chest. Med.</source><year>2013</year><volume>34</volume><fpage>753</fpage><lpage>778</lpage><pub-id pub-id-type="doi">10.1016/j.ccm.2013.08.005</pub-id><pub-id pub-id-type="pmid">24267303</pub-id>
</element-citation></ref><ref id="B14-pharmaceutics-17-00224"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Humbert</surname><given-names>M.</given-names></name>
<name><surname>Guignabert</surname><given-names>C.</given-names></name>
<name><surname>Bonnet</surname><given-names>S.</given-names></name>
<name><surname>Dorfm&#x000fc;ller</surname><given-names>P.</given-names></name>
<name><surname>Klinger</surname><given-names>J.R.</given-names></name>
<name><surname>Nicolls</surname><given-names>M.R.</given-names></name>
<name><surname>Olschewski</surname><given-names>A.J.</given-names></name>
<name><surname>Pullamsetti</surname><given-names>S.S.</given-names></name>
<name><surname>Schermuly</surname><given-names>R.T.</given-names></name>
<name><surname>Stenmark</surname><given-names>K.R.</given-names></name>
<etal/>
</person-group><article-title>Pathology and pathobiology of pulmonary hypertension: State of the art and research perspectives</article-title><source>Eur. Respir. J.</source><year>2019</year><volume>53</volume><fpage>1801887</fpage><pub-id pub-id-type="doi">10.1183/13993003.01887-2018</pub-id><pub-id pub-id-type="pmid">30545970</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00224"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Swinnen</surname><given-names>K.</given-names></name>
<name><surname>Bijnens</surname><given-names>E.</given-names></name>
<name><surname>Casas</surname><given-names>L.</given-names></name>
<name><surname>Nawrot</surname><given-names>T.S.</given-names></name>
<name><surname>Delcroix</surname><given-names>M.</given-names></name>
<name><surname>Quarck</surname><given-names>R.</given-names></name>
<name><surname>Belge</surname><given-names>C.</given-names></name>
</person-group><article-title>Health effects of exposure to residential air pollution in patients with pulmonary arterial hypertension: A cohort study in Belgium</article-title><source>Eur. Respir. J.</source><year>2022</year><volume>60</volume><fpage>2102335</fpage><pub-id pub-id-type="doi">10.1183/13993003.02335-2021</pub-id><pub-id pub-id-type="pmid">35618275</pub-id>
</element-citation></ref><ref id="B16-pharmaceutics-17-00224"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sofianopoulou</surname><given-names>E.</given-names></name>
<name><surname>Kaptoge</surname><given-names>S.</given-names></name>
<name><surname>Gr&#x000e4;f</surname><given-names>S.</given-names></name>
<name><surname>Hadinnapola</surname><given-names>C.</given-names></name>
<name><surname>Treacy</surname><given-names>C.M.</given-names></name>
<name><surname>Church</surname><given-names>C.</given-names></name>
<name><surname>Coghlan</surname><given-names>G.</given-names></name>
<name><surname>Gibbs</surname><given-names>J.S.R.</given-names></name>
<name><surname>Haimel</surname><given-names>M.</given-names></name>
<name><surname>Howard</surname><given-names>L.S.</given-names></name>
<etal/>
</person-group><article-title>Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: A UK cohort study analysis</article-title><source>Eur. Respir. J.</source><year>2019</year><volume>53</volume><fpage>1801429</fpage><pub-id pub-id-type="doi">10.1183/13993003.01429-2018</pub-id><pub-id pub-id-type="pmid">30923185</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00224"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Harrison</surname><given-names>R.E.</given-names></name>
<name><surname>Berger</surname><given-names>R.</given-names></name>
<name><surname>Haworth</surname><given-names>S.G.</given-names></name>
<name><surname>Tulloh</surname><given-names>R.</given-names></name>
<name><surname>Mache</surname><given-names>C.J.</given-names></name>
<name><surname>Morrell</surname><given-names>N.W.</given-names></name>
<name><surname>Aldred</surname><given-names>M.A.</given-names></name>
<name><surname>Trembath</surname><given-names>R.C.</given-names></name>
</person-group><article-title>Transforming Growth Factor-&#x003b2; Receptor Mutations and Pulmonary Arterial Hypertension in Childhood</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>435</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000153798.78540.87</pub-id><pub-id pub-id-type="pmid">15687131</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00224"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Austin</surname><given-names>E.D.</given-names></name>
<name><surname>Ma</surname><given-names>L.</given-names></name>
<name><surname>LeDuc</surname><given-names>C.</given-names></name>
<name><surname>Berman Rosenzweig</surname><given-names>E.</given-names></name>
<name><surname>Borczuk</surname><given-names>A.</given-names></name>
<name><surname>Phillips</surname><given-names>J.A.</given-names></name>
<name><surname>Palomero</surname><given-names>T.</given-names></name>
<name><surname>Sumazin</surname><given-names>P.</given-names></name>
<name><surname>Kim</surname><given-names>H.R.</given-names></name>
<name><surname>Talati</surname><given-names>M.H.</given-names></name>
<etal/>
</person-group><article-title>Whole Exome Sequencing to Identify a Novel Gene (Caveolin-1) Associated With Human Pulmonary Arterial Hypertension</article-title><source>Circ. Cardiovasc. Genet.</source><year>2012</year><volume>5</volume><fpage>336</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1161/CIRCGENETICS.111.961888</pub-id><pub-id pub-id-type="pmid">22474227</pub-id>
</element-citation></ref><ref id="B19-pharmaceutics-17-00224"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barnes</surname><given-names>J.W.</given-names></name>
<name><surname>Kucera</surname><given-names>E.T.</given-names></name>
<name><surname>Tian</surname><given-names>L.</given-names></name>
<name><surname>Mellor</surname><given-names>N.E.</given-names></name>
<name><surname>Dvorina</surname><given-names>N.</given-names></name>
<name><surname>Baldwin</surname><given-names>W.W.</given-names></name>
<name><surname>Aldred</surname><given-names>M.A.</given-names></name>
<name><surname>Farver</surname><given-names>C.F.</given-names></name>
<name><surname>Comhair</surname><given-names>S.A.A.</given-names></name>
<name><surname>Aytekin</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Bone Morphogenic Protein Type 2 Receptor Mutation-Independent Mechanisms of Disrupted Bone Morphogenetic Protein Signaling in Idiopathic Pulmonary Arterial Hypertension</article-title><source>Am. J. Respir. Cell Mol. Biol.</source><year>2016</year><volume>55</volume><fpage>564</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2015-0402OC</pub-id><pub-id pub-id-type="pmid">27187737</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00224"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gr&#x000e4;f</surname><given-names>S.</given-names></name>
<name><surname>Haimel</surname><given-names>M.</given-names></name>
<name><surname>Bleda</surname><given-names>M.</given-names></name>
<name><surname>Hadinnapola</surname><given-names>C.</given-names></name>
<name><surname>Southgate</surname><given-names>L.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Hodgson</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Salmon</surname><given-names>R.M.</given-names></name>
<name><surname>Southwood</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Identification of rare sequence variation underlying heritable pulmonary arterial hypertension</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>1416</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-03672-4</pub-id><pub-id pub-id-type="pmid">29650961</pub-id>
</element-citation></ref><ref id="B21-pharmaceutics-17-00224"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Price</surname><given-names>L.C.</given-names></name>
<name><surname>Wort</surname><given-names>S.J.</given-names></name>
<name><surname>Perros</surname><given-names>F.</given-names></name>
<name><surname>Dorfm&#x000fc;ller</surname><given-names>P.</given-names></name>
<name><surname>Huertas</surname><given-names>A.</given-names></name>
<name><surname>Montani</surname><given-names>D.</given-names></name>
<name><surname>Cohen-Kaminsky</surname><given-names>S.</given-names></name>
<name><surname>Humbert</surname><given-names>M.</given-names></name>
</person-group><article-title>Inflammation in Pulmonary Arterial Hypertension</article-title><source>CHEST</source><year>2012</year><volume>141</volume><fpage>210</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1378/chest.11-0793</pub-id><pub-id pub-id-type="pmid">22215829</pub-id>
</element-citation></ref><ref id="B22-pharmaceutics-17-00224"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Savai</surname><given-names>R.</given-names></name>
<name><surname>Al-Tamari</surname><given-names>H.M.</given-names></name>
<name><surname>Sedding</surname><given-names>D.</given-names></name>
<name><surname>Kojonazarov</surname><given-names>B.</given-names></name>
<name><surname>Muecke</surname><given-names>C.</given-names></name>
<name><surname>Teske</surname><given-names>R.</given-names></name>
<name><surname>Capecchi</surname><given-names>M.R.</given-names></name>
<name><surname>Weissmann</surname><given-names>N.</given-names></name>
<name><surname>Grimminger</surname><given-names>F.</given-names></name>
<name><surname>Seeger</surname><given-names>W.</given-names></name>
<etal/>
</person-group><article-title>Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension</article-title><source>Nat. Med.</source><year>2014</year><volume>20</volume><fpage>1289</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1038/nm.3695</pub-id><pub-id pub-id-type="pmid">25344740</pub-id>
</element-citation></ref><ref id="B23-pharmaceutics-17-00224"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shah</surname><given-names>A.J.</given-names></name>
<name><surname>Beckmann</surname><given-names>T.</given-names></name>
<name><surname>Vorla</surname><given-names>M.</given-names></name>
<name><surname>Kalra</surname><given-names>D.K.</given-names></name>
</person-group><article-title>New Drugs and Therapies in Pulmonary Arterial Hypertension</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>5850</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24065850</pub-id><pub-id pub-id-type="pmid">36982922</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00224"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lang</surname><given-names>I.M.</given-names></name>
<name><surname>Gaine</surname><given-names>S.P.</given-names></name>
</person-group><article-title>Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension</article-title><source>Eur. Respir. Rev.</source><year>2015</year><volume>24</volume><fpage>630</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1183/16000617.0067-2015</pub-id><pub-id pub-id-type="pmid">26621977</pub-id>
</element-citation></ref><ref id="B25-pharmaceutics-17-00224"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mirhadi</surname><given-names>E.</given-names></name>
<name><surname>Kesharwani</surname><given-names>P.</given-names></name>
<name><surname>Johnston</surname><given-names>T.P.</given-names></name>
<name><surname>Sahebkar</surname><given-names>A.</given-names></name>
</person-group><article-title>Nanomedicine-mediated therapeutic approaches for pulmonary arterial hypertension</article-title><source>Drug Discov. Today</source><year>2023</year><volume>28</volume><fpage>103599</fpage><pub-id pub-id-type="doi">10.1016/j.drudis.2023.103599</pub-id><pub-id pub-id-type="pmid">37116826</pub-id>
</element-citation></ref><ref id="B26-pharmaceutics-17-00224"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohamed</surname><given-names>N.A.</given-names></name>
<name><surname>Abou-Saleh</surname><given-names>H.</given-names></name>
<name><surname>Kameno</surname><given-names>Y.</given-names></name>
<name><surname>Marei</surname><given-names>I.</given-names></name>
<name><surname>de Nucci</surname><given-names>G.</given-names></name>
<name><surname>Ahmetaj-Shala</surname><given-names>B.</given-names></name>
<name><surname>Shala</surname><given-names>F.</given-names></name>
<name><surname>Kirkby</surname><given-names>N.S.</given-names></name>
<name><surname>Jennings</surname><given-names>L.</given-names></name>
<name><surname>Al-Ansari</surname><given-names>D.E.</given-names></name>
<etal/>
</person-group><article-title>Studies on metal&#x02013;organic framework (MOF) nanomedicine preparations of sildenafil for the future treatment of pulmonary arterial hypertension</article-title><source>Sci. Rep.</source><year>2021</year><volume>11</volume><elocation-id>4336</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-021-83423-6</pub-id><pub-id pub-id-type="pmid">33619326</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-17-00224"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hanna</surname><given-names>L.A.</given-names></name>
<name><surname>Basalious</surname><given-names>E.B.</given-names></name>
<name><surname>ELGazayerly</surname><given-names>O.N.</given-names></name>
</person-group><article-title>Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: In vitro aerosolization, histological examination and in vivo pulmonary absorption</article-title><source>Drug Deliv.</source><year>2016</year><volume>24</volume><fpage>188</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1080/10717544.2016.1239661</pub-id><pub-id pub-id-type="pmid">28156176</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-17-00224"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rivera-Lebron</surname><given-names>B.N.</given-names></name>
<name><surname>Risbano</surname><given-names>M.G.</given-names></name>
</person-group><article-title>Ambrisentan: A review of its use in pulmonary arterial hypertension</article-title><source>Ther. Adv. Respir. Dis.</source><year>2017</year><volume>11</volume><fpage>233</fpage><lpage>244</lpage><pub-id pub-id-type="doi">10.1177/1753465817696040</pub-id><pub-id pub-id-type="pmid">28425346</pub-id>
</element-citation></ref><ref id="B29-pharmaceutics-17-00224"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kendre</surname><given-names>P.N.</given-names></name>
<name><surname>Chaudhari</surname><given-names>P.D.</given-names></name>
</person-group><article-title>Effect of amphiphilic graft co-polymer-carrier on physical stability of bosentan nanocomposite: Assessment of solubility, dissolution and bioavailability</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2018</year><volume>126</volume><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2017.06.024</pub-id><pub-id pub-id-type="pmid">28655665</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00224"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zancan</surname><given-names>L.R.</given-names></name>
<name><surname>Bruinsmann</surname><given-names>F.A.</given-names></name>
<name><surname>Paese</surname><given-names>K.</given-names></name>
<name><surname>T&#x000fc;rck</surname><given-names>P.</given-names></name>
<name><surname>Bahr</surname><given-names>A.</given-names></name>
<name><surname>Zimmer</surname><given-names>A.</given-names></name>
<name><surname>Carraro</surname><given-names>C.C.</given-names></name>
<name><surname>Schenkel</surname><given-names>P.C.</given-names></name>
<name><surname>Bell&#x000f3;-Klein</surname><given-names>A.</given-names></name>
<name><surname>Schwertz</surname><given-names>C.I.</given-names></name>
<etal/>
</person-group><article-title>Oral delivery of ambrisentan-loaded lipid-core nanocapsules as a novel approach for the treatment of pulmonary arterial hypertension</article-title><source>Int. J. Pharm.</source><year>2021</year><volume>610</volume><fpage>121181</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.121181</pub-id><pub-id pub-id-type="pmid">34653563</pub-id>
</element-citation></ref><ref id="B31-pharmaceutics-17-00224"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rashid</surname><given-names>J.</given-names></name>
<name><surname>Patel</surname><given-names>B.</given-names></name>
<name><surname>Nozik-Grayck</surname><given-names>E.</given-names></name>
<name><surname>McMurtry</surname><given-names>I.F.</given-names></name>
<name><surname>Stenmark</surname><given-names>K.R.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH)</article-title><source>J. Control. Release</source><year>2017</year><volume>250</volume><fpage>96</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.02.003</pub-id><pub-id pub-id-type="pmid">28185800</pub-id>
</element-citation></ref><ref id="B32-pharmaceutics-17-00224"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>T.-T.</given-names></name>
<name><surname>Yi</surname><given-names>E.-J.</given-names></name>
<name><surname>Hwang</surname><given-names>K.-M.</given-names></name>
<name><surname>Cho</surname><given-names>C.-H.</given-names></name>
<name><surname>Park</surname><given-names>C.-W.</given-names></name>
<name><surname>Kim</surname><given-names>J.-Y.</given-names></name>
<name><surname>Rhee</surname><given-names>Y.-S.</given-names></name>
<name><surname>Park</surname><given-names>E.-S.</given-names></name>
</person-group><article-title>Formulation and evaluation of carrier-free dry powder inhaler containing sildenafil</article-title><source>Drug Deliv. Transl. Res.</source><year>2019</year><volume>9</volume><fpage>319</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1007/s13346-018-0586-5</pub-id><pub-id pub-id-type="pmid">30276666</pub-id>
</element-citation></ref><ref id="B33-pharmaceutics-17-00224"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McCullough</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Four-year review of sildenafil citrate</article-title><source>Rev. Urol.</source><year>2002</year><volume>4</volume><issue>(Suppl. 3)</issue><fpage>S26</fpage><lpage>S38</lpage><pub-id pub-id-type="pmid">16986012</pub-id>
</element-citation></ref><ref id="B34-pharmaceutics-17-00224"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhogal</surname><given-names>S.</given-names></name>
<name><surname>Khraisha</surname><given-names>O.</given-names></name>
<name><surname>Al Madani</surname><given-names>M.</given-names></name>
<name><surname>Treece</surname><given-names>J.</given-names></name>
<name><surname>Baumrucker</surname><given-names>S.J.</given-names></name>
<name><surname>Paul</surname><given-names>T.K.</given-names></name>
</person-group><article-title>Sildenafil for Pulmonary Arterial Hypertension</article-title><source>Am. J. Ther.</source><year>2019</year><volume>26</volume><fpage>e520</fpage><lpage>e526</lpage><pub-id pub-id-type="doi">10.1097/MJT.0000000000000766</pub-id><pub-id pub-id-type="pmid">30946047</pub-id>
</element-citation></ref><ref id="B35-pharmaceutics-17-00224"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jain</surname><given-names>S.</given-names></name>
<name><surname>Kumar</surname><given-names>N.</given-names></name>
<name><surname>Sharma</surname><given-names>R.</given-names></name>
<name><surname>Ghadi</surname><given-names>R.</given-names></name>
<name><surname>Date</surname><given-names>T.</given-names></name>
<name><surname>Bhargavi</surname><given-names>N.</given-names></name>
<name><surname>Chaudhari</surname><given-names>D.</given-names></name>
<name><surname>Katiyar</surname><given-names>S.S.</given-names></name>
</person-group><article-title>Self-nanoemulsifying formulation for oral delivery of sildenafil: Effect on physicochemical attributes and in vivo pharmacokinetics</article-title><source>Drug Deliv. Transl. Res.</source><year>2023</year><volume>13</volume><fpage>839</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.1007/s13346-022-01247-x</pub-id><pub-id pub-id-type="pmid">36223029</pub-id>
</element-citation></ref><ref id="B36-pharmaceutics-17-00224"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Elbardisy</surname><given-names>B.</given-names></name>
<name><surname>Boraie</surname><given-names>N.</given-names></name>
<name><surname>Galal</surname><given-names>S.</given-names></name>
</person-group><article-title>Tadalafil nanoemulsion mists for treatment of pediatric pulmonary hypertension via nebulization</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>2717</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14122717</pub-id><pub-id pub-id-type="pmid">36559211</pub-id>
</element-citation></ref><ref id="B37-pharmaceutics-17-00224"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fan</surname><given-names>Y.F.</given-names></name>
<name><surname>Zhang</surname><given-names>R.</given-names></name>
<name><surname>Jiang</surname><given-names>X.</given-names></name>
<name><surname>Wen</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>D.C.</given-names></name>
<name><surname>Liu</surname><given-names>D.</given-names></name>
<name><surname>Yuan</surname><given-names>P.</given-names></name>
<name><surname>Wang</surname><given-names>Y.L.</given-names></name>
<name><surname>Jing</surname><given-names>Z.C.</given-names></name>
</person-group><article-title>The phosphodiesterase-5 inhibitor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension</article-title><source>Cardiovasc. Res.</source><year>2013</year><volume>99</volume><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvt109</pub-id><pub-id pub-id-type="pmid">23650288</pub-id>
</element-citation></ref><ref id="B38-pharmaceutics-17-00224"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jing</surname><given-names>Z.C.</given-names></name>
<name><surname>Yu</surname><given-names>Z.X.</given-names></name>
<name><surname>Shen</surname><given-names>J.Y.</given-names></name>
<name><surname>Wu</surname><given-names>B.X.</given-names></name>
<name><surname>Xu</surname><given-names>K.F.</given-names></name>
<name><surname>Zhu</surname><given-names>X.Y.</given-names></name>
<name><surname>Pan</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>Z.L.</given-names></name>
<name><surname>Liu</surname><given-names>X.Q.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.S.</given-names></name>
<etal/>
</person-group><article-title>Vardenafil in pulmonary arterial hypertension: A randomized, double-blind, placebo-controlled study</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>2011</year><volume>183</volume><fpage>1723</fpage><lpage>1729</lpage><pub-id pub-id-type="doi">10.1164/rccm.201101-0093OC</pub-id><pub-id pub-id-type="pmid">21471085</pub-id>
</element-citation></ref><ref id="B39-pharmaceutics-17-00224"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melian</surname><given-names>E.B.</given-names></name>
<name><surname>Goa</surname><given-names>K.L.</given-names></name>
</person-group><article-title>Beraprost</article-title><source>Drugs</source><year>2002</year><volume>62</volume><fpage>107</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.2165/00003495-200262010-00005</pub-id><pub-id pub-id-type="pmid">11790158</pub-id>
</element-citation></ref><ref id="B40-pharmaceutics-17-00224"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tuder</surname><given-names>R.M.</given-names></name>
<name><surname>Cool</surname><given-names>C.D.</given-names></name>
<name><surname>Geraci</surname><given-names>M.W.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Abman</surname><given-names>S.H.</given-names></name>
<name><surname>Wright</surname><given-names>L.</given-names></name>
<name><surname>Badesch</surname><given-names>D.</given-names></name>
<name><surname>Voelkel</surname><given-names>N.F.</given-names></name>
</person-group><article-title>Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension</article-title><source>Am. J. Respir. Crit. Care Med.</source><year>1999</year><volume>159</volume><fpage>1925</fpage><lpage>1932</lpage><pub-id pub-id-type="doi">10.1164/ajrccm.159.6.9804054</pub-id><pub-id pub-id-type="pmid">10351941</pub-id>
</element-citation></ref><ref id="B41-pharmaceutics-17-00224"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Clapp</surname><given-names>L.H.</given-names></name>
<name><surname>Finney</surname><given-names>P.</given-names></name>
<name><surname>Turcato</surname><given-names>S.</given-names></name>
<name><surname>Tran</surname><given-names>S.</given-names></name>
<name><surname>Rubin</surname><given-names>L.J.</given-names></name>
<name><surname>Tinker</surname><given-names>A.</given-names></name>
</person-group><article-title>Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery</article-title><source>Am. J. Respir. Cell. Mol. Biol.</source><year>2002</year><volume>26</volume><fpage>194</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1165/ajrcmb.26.2.4695</pub-id><pub-id pub-id-type="pmid">11804870</pub-id>
</element-citation></ref><ref id="B42-pharmaceutics-17-00224"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishihara</surname><given-names>T.</given-names></name>
<name><surname>Hayashi</surname><given-names>E.</given-names></name>
<name><surname>Yamamoto</surname><given-names>S.</given-names></name>
<name><surname>Kobayashi</surname><given-names>C.</given-names></name>
<name><surname>Tamura</surname><given-names>Y.</given-names></name>
<name><surname>Sawazaki</surname><given-names>R.</given-names></name>
<name><surname>Tamura</surname><given-names>F.</given-names></name>
<name><surname>Tahara</surname><given-names>K.</given-names></name>
<name><surname>Kasahara</surname><given-names>T.</given-names></name>
<name><surname>Ishihara</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Encapsulation of beraprost sodium in nanoparticles: Analysis of sustained release properties, targeting abilities and pharmacological activities in animal models of pulmonary arterial hypertension</article-title><source>J. Control. Release</source><year>2015</year><volume>197</volume><fpage>97</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2014.10.029</pub-id><pub-id pub-id-type="pmid">25449809</pub-id>
</element-citation></ref><ref id="B43-pharmaceutics-17-00224"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jain</surname><given-names>P.P.</given-names></name>
<name><surname>Leber</surname><given-names>R.</given-names></name>
<name><surname>Nagaraj</surname><given-names>C.</given-names></name>
<name><surname>Leitinger</surname><given-names>G.</given-names></name>
<name><surname>Lehofer</surname><given-names>B.</given-names></name>
<name><surname>Olschewski</surname><given-names>H.</given-names></name>
<name><surname>Olschewski</surname><given-names>A.</given-names></name>
<name><surname>Prassl</surname><given-names>R.</given-names></name>
<name><surname>Marsh</surname><given-names>L.M.</given-names></name>
</person-group><article-title>Liposomal nanoparticles encapsulating iloprost exhibit enhanced vasodilation in pulmonary arteries</article-title><source>Int. J. Nanomed.</source><year>2014</year><volume>9</volume><fpage>3249</fpage><lpage>3261</lpage><pub-id pub-id-type="doi">10.2147/IJN.S63190</pub-id></element-citation></ref><ref id="B44-pharmaceutics-17-00224"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Plaunt</surname><given-names>A.J.</given-names></name>
<name><surname>Islam</surname><given-names>S.</given-names></name>
<name><surname>Macaluso</surname><given-names>T.</given-names></name>
<name><surname>Gauani</surname><given-names>H.</given-names></name>
<name><surname>Baker</surname><given-names>T.</given-names></name>
<name><surname>Chun</surname><given-names>D.</given-names></name>
<name><surname>Viramontes</surname><given-names>V.</given-names></name>
<name><surname>Chang</surname><given-names>C.</given-names></name>
<name><surname>Corboz</surname><given-names>M.R.</given-names></name>
<name><surname>Chapman</surname><given-names>R.W.</given-names></name>
<etal/>
</person-group><article-title>Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension</article-title><source>Int. J. Mol. Sci.</source><year>2021</year><volume>22</volume><elocation-id>548</elocation-id><pub-id pub-id-type="doi">10.3390/ijms22020548</pub-id><pub-id pub-id-type="pmid">33430435</pub-id>
</element-citation></ref><ref id="B45-pharmaceutics-17-00224"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nossaman</surname><given-names>B.</given-names></name>
<name><surname>Pankey</surname><given-names>E.</given-names></name>
<name><surname>Kadowitz</surname><given-names>P.</given-names></name>
</person-group><article-title>Stimulators and activators of soluble guanylate cyclase: Review and potential therapeutic indications</article-title><source>Crit. Care Res. Pract.</source><year>2012</year><volume>2012</volume><fpage>290805</fpage><pub-id pub-id-type="doi">10.1155/2012/290805</pub-id><pub-id pub-id-type="pmid">22482042</pub-id>
</element-citation></ref><ref id="B46-pharmaceutics-17-00224"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ghofrani</surname><given-names>H.-A.</given-names></name>
<name><surname>Gali&#x000e8;</surname><given-names>N.</given-names></name>
<name><surname>Grimminger</surname><given-names>F.</given-names></name>
<name><surname>Gr&#x000fc;nig</surname><given-names>E.</given-names></name>
<name><surname>Humbert</surname><given-names>M.</given-names></name>
<name><surname>Jing</surname><given-names>Z.-C.</given-names></name>
<name><surname>Keogh</surname><given-names>A.M.</given-names></name>
<name><surname>Langleben</surname><given-names>D.</given-names></name>
<name><surname>Kilama</surname><given-names>M.O.</given-names></name>
<name><surname>Fritsch</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Riociguat for the Treatment of Pulmonary Arterial Hypertension</article-title><source>N. Engl. J. Med.</source><year>2013</year><volume>369</volume><fpage>330</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1209655</pub-id><pub-id pub-id-type="pmid">23883378</pub-id>
</element-citation></ref><ref id="B47-pharmaceutics-17-00224"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>N.</given-names></name>
<name><surname>Rashid</surname><given-names>J.</given-names></name>
<name><surname>Nozik-Grayck</surname><given-names>E.</given-names></name>
<name><surname>McMurtry</surname><given-names>I.F.</given-names></name>
<name><surname>Stenmark</surname><given-names>K.R.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency</article-title><source>Mol. Pharm.</source><year>2017</year><volume>14</volume><fpage>830</fpage><lpage>841</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.6b01061</pub-id><pub-id pub-id-type="pmid">28165252</pub-id>
</element-citation></ref><ref id="B48-pharmaceutics-17-00224"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>V.</given-names></name>
<name><surname>Gupta</surname><given-names>N.</given-names></name>
<name><surname>Shaik</surname><given-names>I.H.</given-names></name>
<name><surname>Mehvar</surname><given-names>R.</given-names></name>
<name><surname>McMurtry</surname><given-names>I.F.</given-names></name>
<name><surname>Oka</surname><given-names>M.</given-names></name>
<name><surname>Nozik-Grayck</surname><given-names>E.</given-names></name>
<name><surname>Komatsu</surname><given-names>M.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension</article-title><source>J. Control. Release</source><year>2013</year><volume>167</volume><fpage>189</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2013.01.011</pub-id><pub-id pub-id-type="pmid">23353807</pub-id>
</element-citation></ref><ref id="B49-pharmaceutics-17-00224"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meloche</surname><given-names>J.</given-names></name>
<name><surname>Renard</surname><given-names>S.</given-names></name>
<name><surname>Provencher</surname><given-names>S.</given-names></name>
<name><surname>Bonnet</surname><given-names>S.</given-names></name>
</person-group><article-title>Anti-inflammatory and immunosuppressive agents in PAH</article-title><source>Handb. Exp. Pharmacol.</source><year>2013</year><volume>218</volume><fpage>437</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-38664-0_18</pub-id><pub-id pub-id-type="pmid">24092351</pub-id>
</element-citation></ref><ref id="B50-pharmaceutics-17-00224"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haddad</surname><given-names>F.</given-names></name>
<name><surname>Mohammed</surname><given-names>N.</given-names></name>
<name><surname>Gopalan</surname><given-names>R.C.</given-names></name>
<name><surname>Ayoub</surname><given-names>Y.A.</given-names></name>
<name><surname>Nasim</surname><given-names>M.T.</given-names></name>
<name><surname>Assi</surname><given-names>K.H.</given-names></name>
</person-group><article-title>Development and Optimisation of Inhalable EGCG Nano-Liposomes as a Potential Treatment for Pulmonary Arterial Hypertension by Implementation of the Design of Experiments Approach</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>539</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15020539</pub-id><pub-id pub-id-type="pmid">36839861</pub-id>
</element-citation></ref><ref id="B51-pharmaceutics-17-00224"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>K.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Cao</surname><given-names>G.</given-names></name>
<name><surname>Liu</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Sun</surname><given-names>H.</given-names></name>
<name><surname>Pang</surname><given-names>X.</given-names></name>
</person-group><article-title>Intratracheal instillation of ethyl pyruvate nanoparticles prevents the development of shunt-flow-induced pulmonary arterial hypertension in a rat model</article-title><source>Int. J. Nanomed.</source><year>2016</year><volume>11</volume><fpage>2587</fpage><lpage>2599</lpage><pub-id pub-id-type="doi">10.2147/IJN.S103183</pub-id></element-citation></ref><ref id="B52-pharmaceutics-17-00224"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuang</surname><given-names>T.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Pang</surname><given-names>B.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Burg</surname><given-names>E.D.</given-names></name>
<name><surname>Yuan</surname><given-names>J.X.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
</person-group><article-title>Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats</article-title><source>Pulm. Pharmacol. Ther.</source><year>2010</year><volume>23</volume><fpage>456</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1016/j.pupt.2010.02.003</pub-id><pub-id pub-id-type="pmid">20188205</pub-id>
</element-citation></ref><ref id="B53-pharmaceutics-17-00224"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Usta</surname><given-names>D.Y.</given-names></name>
<name><surname>Timur</surname><given-names>B.</given-names></name>
<name><surname>Teksin</surname><given-names>Z.S.</given-names></name>
</person-group><article-title>Formulation development, optimization by Box-Behnken design, characterization, in vitro, ex-vivo, and in vivo evaluation of bosentan-loaded self-nanoemulsifying drug delivery system: A novel alternative dosage form for pulmonary arterial hypertension treatment</article-title><source>Eur. J. Pharm. Sci.</source><year>2022</year><volume>174</volume><fpage>106159</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2022.106159</pub-id><pub-id pub-id-type="pmid">35263632</pub-id>
</element-citation></ref><ref id="B54-pharmaceutics-17-00224"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>He</surname><given-names>W.</given-names></name>
<name><surname>Ye</surname><given-names>L.</given-names></name>
<name><surname>Zhu</surname><given-names>Y.</given-names></name>
<name><surname>Tian</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Yang</surname><given-names>J.</given-names></name>
<name><surname>Miao</surname><given-names>M.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Azevedo</surname><given-names>H.S.</given-names></name>
<etal/>
</person-group><article-title>Targeted Delivery of Sildenafil for Inhibiting Pulmonary Vascular Remodeling</article-title><source>Hypertension</source><year>2019</year><volume>73</volume><fpage>703</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.118.11932</pub-id><pub-id pub-id-type="pmid">30636546</pub-id>
</element-citation></ref><ref id="B55-pharmaceutics-17-00224"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Almutairi</surname><given-names>M.</given-names></name>
<name><surname>Hefnawy</surname><given-names>A.</given-names></name>
<name><surname>Almotairy</surname><given-names>A.</given-names></name>
<name><surname>Alobaida</surname><given-names>A.</given-names></name>
<name><surname>Alyahya</surname><given-names>M.</given-names></name>
<name><surname>Althobaiti</surname><given-names>A.</given-names></name>
<name><surname>Adel Ali Youssef</surname><given-names>A.</given-names></name>
<name><surname>Elkanayati</surname><given-names>R.M.</given-names></name>
<name><surname>Ashour</surname><given-names>E.A.</given-names></name>
<name><surname>Smyth</surname><given-names>H.D.C.</given-names></name>
<etal/>
</person-group><article-title>Formulation and evaluation of inhaled Sildenafil-loaded PLGA microparticles for treatment of pulmonary arterial hypertension (PAH): A novel high drug loaded formulation and scalable process via hot melt extrusion technology (Part I)</article-title><source>Int. J. Pharm.</source><year>2024</year><volume>655</volume><fpage>124044</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2024.124044</pub-id><pub-id pub-id-type="pmid">38527563</pub-id>
</element-citation></ref><ref id="B56-pharmaceutics-17-00224"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rashid</surname><given-names>J.</given-names></name>
<name><surname>Nozik-Grayck</surname><given-names>E.</given-names></name>
<name><surname>McMurtry</surname><given-names>I.F.</given-names></name>
<name><surname>Stenmark</surname><given-names>K.R.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Inhaled combination of sildenafil and rosiglitazone improves pulmonary hemodynamics, cardiac function, and arterial remodeling</article-title><source>Am. J. Physiol. Lung Cell. Mol. Physiol.</source><year>2019</year><volume>316</volume><fpage>L119</fpage><lpage>L130</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00381.2018</pub-id><pub-id pub-id-type="pmid">30307312</pub-id>
</element-citation></ref><ref id="B57-pharmaceutics-17-00224"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakamura</surname><given-names>K.</given-names></name>
<name><surname>Akagi</surname><given-names>S.</given-names></name>
<name><surname>Ejiri</surname><given-names>K.</given-names></name>
<name><surname>Yoshida</surname><given-names>M.</given-names></name>
<name><surname>Miyoshi</surname><given-names>T.</given-names></name>
<name><surname>Toh</surname><given-names>N.</given-names></name>
<name><surname>Nakagawa</surname><given-names>K.</given-names></name>
<name><surname>Takaya</surname><given-names>Y.</given-names></name>
<name><surname>Matsubara</surname><given-names>H.</given-names></name>
<name><surname>Ito</surname><given-names>H.</given-names></name>
</person-group><article-title>Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension</article-title><source>Int. J. Mol. Sci.</source><year>2019</year><volume>20</volume><elocation-id>5885</elocation-id><pub-id pub-id-type="doi">10.3390/ijms20235885</pub-id><pub-id pub-id-type="pmid">31771203</pub-id>
</element-citation></ref><ref id="B58-pharmaceutics-17-00224"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akagi</surname><given-names>S.</given-names></name>
<name><surname>Nakamura</surname><given-names>K.</given-names></name>
<name><surname>Matsubara</surname><given-names>H.</given-names></name>
<name><surname>Kondo</surname><given-names>M.</given-names></name>
<name><surname>Miura</surname><given-names>D.</given-names></name>
<name><surname>Matoba</surname><given-names>T.</given-names></name>
<name><surname>Egashira</surname><given-names>K.</given-names></name>
<name><surname>Ito</surname><given-names>H.</given-names></name>
</person-group><article-title>Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension</article-title><source>J. Cardiovasc. Pharmacol.</source><year>2016</year><volume>67</volume><fpage>290</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1097/FJC.0000000000000352</pub-id><pub-id pub-id-type="pmid">26745002</pub-id>
</element-citation></ref><ref id="B59-pharmaceutics-17-00224"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>A.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Yang</surname><given-names>M.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Su</surname><given-names>J.</given-names></name>
</person-group><article-title>Targeted treprostinil delivery inhibits pulmonary arterial remodeling</article-title><source>Eur. J. Pharmacol.</source><year>2022</year><volume>923</volume><fpage>174700</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2021.174700</pub-id><pub-id pub-id-type="pmid">35131313</pub-id>
</element-citation></ref><ref id="B60-pharmaceutics-17-00224"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keshavarz</surname><given-names>A.</given-names></name>
<name><surname>Alobaida</surname><given-names>A.</given-names></name>
<name><surname>McMurtry</surname><given-names>I.F.</given-names></name>
<name><surname>Nozik-Grayck</surname><given-names>E.</given-names></name>
<name><surname>Stenmark</surname><given-names>K.R.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>CAR, a homing peptide, prolongs pulmonary preferential vasodilation by increasing pulmonary retention and reducing systemic absorption of liposomal fasudil</article-title><source>Mol. Pharm.</source><year>2019</year><volume>16</volume><fpage>3414</fpage><lpage>3429</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b00208</pub-id><pub-id pub-id-type="pmid">31194563</pub-id>
</element-citation></ref><ref id="B61-pharmaceutics-17-00224"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>N.</given-names></name>
<name><surname>Al-Saikhan</surname><given-names>F.I.</given-names></name>
<name><surname>Patel</surname><given-names>B.</given-names></name>
<name><surname>Rashid</surname><given-names>J.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Fasudil and SOD packaged in peptide-studded-liposomes: Properties, pharmacokinetics and ex-vivo targeting to isolated perfused rat lungs</article-title><source>Int. J. Pharm.</source><year>2015</year><volume>488</volume><fpage>33</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2015.04.031</pub-id><pub-id pub-id-type="pmid">25888802</pub-id>
</element-citation></ref><ref id="B62-pharmaceutics-17-00224"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>N.</given-names></name>
<name><surname>Patel</surname><given-names>B.</given-names></name>
<name><surname>Nahar</surname><given-names>K.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Cell permeable peptide conjugated nanoerythrosomes of fasudil prolong pulmonary arterial vasodilation in PAH rats</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2014</year><volume>88</volume><fpage>1046</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2014.10.012</pub-id><pub-id pub-id-type="pmid">25460151</pub-id>
</element-citation></ref><ref id="B63-pharmaceutics-17-00224"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Newman</surname><given-names>S.P.</given-names></name>
</person-group><article-title>Drug Delivery to the lungs: Challenges and Opportunities</article-title><source>Ther. Deliv.</source><year>2017</year><volume>8</volume><fpage>647</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.4155/tde-2017-0037</pub-id><pub-id pub-id-type="pmid">28730933</pub-id>
</element-citation></ref><ref id="B64-pharmaceutics-17-00224"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Y&#x00131;ld&#x00131;z-Pek&#x000f6;z</surname><given-names>A.</given-names></name>
<name><surname>Ehrhardt</surname><given-names>C.</given-names></name>
</person-group><article-title>Advances in Pulmonary Drug Delivery</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>911</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12100911</pub-id><pub-id pub-id-type="pmid">32977672</pub-id>
</element-citation></ref><ref id="B65-pharmaceutics-17-00224"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patil</surname><given-names>J.S.</given-names></name>
<name><surname>Sarasija</surname><given-names>S.</given-names></name>
</person-group><article-title>Pulmonary drug delivery strategies: A concise, systematic review</article-title><source>Lung India</source><year>2012</year><volume>29</volume><fpage>44</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.4103/0970-2113.92361</pub-id><pub-id pub-id-type="pmid">22345913</pub-id>
</element-citation></ref><ref id="B66-pharmaceutics-17-00224"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Patwa</surname><given-names>A.</given-names></name>
<name><surname>Shah</surname><given-names>A.</given-names></name>
</person-group><article-title>Anatomy and physiology of respiratory system relevant to anaesthesia</article-title><source>Indian J. Anaesth.</source><year>2015</year><volume>59</volume><fpage>533</fpage><lpage>541</lpage><pub-id pub-id-type="doi">10.4103/0019-5049.165849</pub-id><pub-id pub-id-type="pmid">26556911</pub-id>
</element-citation></ref><ref id="B67-pharmaceutics-17-00224"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scheuch</surname><given-names>G.</given-names></name>
<name><surname>Kohlhaeufl</surname><given-names>M.J.</given-names></name>
<name><surname>Brand</surname><given-names>P.</given-names></name>
<name><surname>Siekmeier</surname><given-names>R.</given-names></name>
</person-group><article-title>Clinical perspectives on pulmonary systemic and macromolecular delivery</article-title><source>Adv. Drug Deliv. Rev.</source><year>2006</year><volume>58</volume><fpage>996</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2006.07.009</pub-id><pub-id pub-id-type="pmid">16996638</pub-id>
</element-citation></ref><ref id="B68-pharmaceutics-17-00224"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liang</surname><given-names>Z.</given-names></name>
<name><surname>Ni</surname><given-names>R.</given-names></name>
<name><surname>Zhou</surname><given-names>J.</given-names></name>
<name><surname>Mao</surname><given-names>S.</given-names></name>
</person-group><article-title>Recent advances in controlled pulmonary drug delivery</article-title><source>Drug Discov. Today</source><year>2015</year><volume>20</volume><fpage>380</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2014.09.020</pub-id><pub-id pub-id-type="pmid">25281854</pub-id>
</element-citation></ref><ref id="B69-pharmaceutics-17-00224"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bisserier</surname><given-names>M.</given-names></name>
<name><surname>Mathiyalagan</surname><given-names>P.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Elmastour</surname><given-names>F.</given-names></name>
<name><surname>Dorfm&#x000fc;ller</surname><given-names>P.</given-names></name>
<name><surname>Humbert</surname><given-names>M.</given-names></name>
<name><surname>David</surname><given-names>G.</given-names></name>
<name><surname>Tarzami</surname><given-names>S.</given-names></name>
<name><surname>Weber</surname><given-names>T.</given-names></name>
<name><surname>Perros</surname><given-names>F.</given-names></name>
</person-group><article-title>Regulation of the methylation and expression levels of the BMPR2 gene by SIN3a as a novel therapeutic mechanism in pulmonary arterial hypertension</article-title><source>Circulation</source><year>2021</year><volume>144</volume><fpage>52</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.047978</pub-id><pub-id pub-id-type="pmid">34078089</pub-id>
</element-citation></ref><ref id="B70-pharmaceutics-17-00224"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yu</surname><given-names>Q.</given-names></name>
<name><surname>Tai</surname><given-names>Y.-Y.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Negi</surname><given-names>V.</given-names></name>
<name><surname>Culley</surname><given-names>M.K.</given-names></name>
<name><surname>Pilli</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>W.</given-names></name>
<name><surname>Brugger</surname><given-names>K.</given-names></name>
<name><surname>Mayr</surname><given-names>J.</given-names></name>
</person-group><article-title>BOLA (BolA Family Member 3) deficiency controls endothelial metabolism and glycine homeostasis in pulmonary hypertension</article-title><source>Circulation</source><year>2019</year><volume>139</volume><fpage>2238</fpage><lpage>2255</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.035889</pub-id><pub-id pub-id-type="pmid">30759996</pub-id>
</element-citation></ref><ref id="B71-pharmaceutics-17-00224"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eid</surname><given-names>H.M.</given-names></name>
<name><surname>Turkia</surname><given-names>T.H.</given-names></name>
<name><surname>Ali</surname><given-names>A.A.</given-names></name>
<name><surname>Aboud</surname><given-names>H.M.</given-names></name>
</person-group><article-title>A Novel Chitosan-coated Leciplex Loaded with Ambrisentan as a Possible Pulmonary Nanosystem: Optimization, Characterization, and Pharmacokinetics Assessments</article-title><source>J. Pharm. Sci.</source><year>2024</year><volume>113</volume><fpage>2320</fpage><lpage>2330</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2024.03.027</pub-id><pub-id pub-id-type="pmid">38582282</pub-id>
</element-citation></ref><ref id="B72-pharmaceutics-17-00224"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ferguson</surname><given-names>S.K.</given-names></name>
<name><surname>Pak</surname><given-names>D.I.</given-names></name>
<name><surname>Hopkins</surname><given-names>J.L.</given-names></name>
<name><surname>Harral</surname><given-names>J.W.</given-names></name>
<name><surname>Redinius</surname><given-names>K.M.</given-names></name>
<name><surname>Loomis</surname><given-names>Z.</given-names></name>
<name><surname>Stenmark</surname><given-names>K.R.</given-names></name>
<name><surname>Borden</surname><given-names>M.A.</given-names></name>
<name><surname>Schroeder</surname><given-names>T.</given-names></name>
<name><surname>Irwin</surname><given-names>D.C.</given-names></name>
</person-group><article-title>Pre-clinical assessment of a water-in-fluorocarbon emulsion for the treatment of pulmonary vascular diseases</article-title><source>Drug Deliv.</source><year>2019</year><volume>26</volume><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1080/10717544.2019.1568621</pub-id><pub-id pub-id-type="pmid">30822171</pub-id>
</element-citation></ref><ref id="B73-pharmaceutics-17-00224"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nahar</surname><given-names>K.</given-names></name>
<name><surname>Rashid</surname><given-names>J.</given-names></name>
<name><surname>Absar</surname><given-names>S.</given-names></name>
<name><surname>Al-Saikhan</surname><given-names>F.I.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Liposomal aerosols of nitric oxide (NO) donor as a long-acting substitute for the ultra-short-acting inhaled NO in the treatment of PAH</article-title><source>Pharm. Res.</source><year>2016</year><volume>33</volume><fpage>1696</fpage><lpage>1710</lpage><pub-id pub-id-type="doi">10.1007/s11095-016-1911-7</pub-id><pub-id pub-id-type="pmid">27048347</pub-id>
</element-citation></ref><ref id="B74-pharmaceutics-17-00224"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ni</surname><given-names>R.</given-names></name>
<name><surname>Muenster</surname><given-names>U.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Becker-Pelster</surname><given-names>E.-M.</given-names></name>
<name><surname>Rosenbruch</surname><given-names>M.</given-names></name>
<name><surname>Mao</surname><given-names>S.</given-names></name>
</person-group><article-title>Exploring polyvinylpyrrolidone in the engineering of large porous PLGA microparticles via single emulsion method with tunable sustained release in the lung: In vitro and in vivo characterization</article-title><source>J. Control. Release</source><year>2017</year><volume>249</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.01.023</pub-id><pub-id pub-id-type="pmid">28109773</pub-id>
</element-citation></ref><ref id="B75-pharmaceutics-17-00224"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>Y.</given-names></name>
<name><surname>Pai</surname><given-names>S.B.</given-names></name>
<name><surname>Bellamkonda</surname><given-names>R.V.</given-names></name>
<name><surname>Thompson</surname><given-names>D.H.</given-names></name>
<name><surname>Singh</surname><given-names>J.</given-names></name>
</person-group><article-title>Cerivastatin nanoliposome as a potential disease modifying approach for the treatment of pulmonary arterial hypertension</article-title><source>J. Pharmacol. Exp. Ther.</source><year>2018</year><volume>366</volume><fpage>66</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1124/jpet.118.247643</pub-id><pub-id pub-id-type="pmid">29695410</pub-id>
</element-citation></ref><ref id="B76-pharmaceutics-17-00224"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Hao</surname><given-names>L.-Z.</given-names></name>
<name><surname>Pan</surname><given-names>J.-A.</given-names></name>
<name><surname>Gao</surname><given-names>Q.</given-names></name>
<name><surname>Zhang</surname><given-names>J.-F.</given-names></name>
<name><surname>Kankala</surname><given-names>R.K.</given-names></name>
<name><surname>Wang</surname><given-names>S.-B.</given-names></name>
<name><surname>Chen</surname><given-names>A.-Z.</given-names></name>
<name><surname>Zhang</surname><given-names>H.-L.</given-names></name>
</person-group><article-title>Microfluidic fabrication of inhalable large porous microspheres loaded with H2S-releasing aspirin derivative for pulmonary arterial hypertension therapy</article-title><source>J. Control. Release</source><year>2021</year><volume>329</volume><fpage>286</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.11.060</pub-id><pub-id pub-id-type="pmid">33279605</pub-id>
</element-citation></ref><ref id="B77-pharmaceutics-17-00224"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ntokou</surname><given-names>A.</given-names></name>
<name><surname>Dave</surname><given-names>J.M.</given-names></name>
<name><surname>Kauffman</surname><given-names>A.C.</given-names></name>
<name><surname>Sauler</surname><given-names>M.</given-names></name>
<name><surname>Ryu</surname><given-names>C.</given-names></name>
<name><surname>Hwa</surname><given-names>J.</given-names></name>
<name><surname>Herzog</surname><given-names>E.L.</given-names></name>
<name><surname>Singh</surname><given-names>I.</given-names></name>
<name><surname>Saltzman</surname><given-names>W.M.</given-names></name>
<name><surname>Greif</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Macrophage-derived PDGF-B induces muscularization in murine and human pulmonary hypertension</article-title><source>JCI Insight</source><year>2021</year><volume>6</volume><fpage>e139067</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.139067</pub-id><pub-id pub-id-type="pmid">33591958</pub-id>
</element-citation></ref><ref id="B78-pharmaceutics-17-00224"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kimura</surname><given-names>S.</given-names></name>
<name><surname>Egashira</surname><given-names>K.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Nakano</surname><given-names>K.</given-names></name>
<name><surname>Iwata</surname><given-names>E.</given-names></name>
<name><surname>Miyagawa</surname><given-names>M.</given-names></name>
<name><surname>Tsujimoto</surname><given-names>H.</given-names></name>
<name><surname>Hara</surname><given-names>K.</given-names></name>
<name><surname>Morishita</surname><given-names>R.</given-names></name>
<name><surname>Sueishi</surname><given-names>K.</given-names></name>
</person-group><article-title>Nanoparticle-mediated delivery of nuclear factor &#x003ba;B decoy into lungs ameliorates monocrotaline-induced pulmonary arterial hypertension</article-title><source>Hypertension</source><year>2009</year><volume>53</volume><fpage>877</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1161/HYPERTENSIONAHA.108.121418</pub-id><pub-id pub-id-type="pmid">19307469</pub-id>
</element-citation></ref><ref id="B79-pharmaceutics-17-00224"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shahin</surname><given-names>H.I.</given-names></name>
<name><surname>Vinjamuri</surname><given-names>B.P.</given-names></name>
<name><surname>Mahmoud</surname><given-names>A.A.</given-names></name>
<name><surname>Shamma</surname><given-names>R.N.</given-names></name>
<name><surname>Mansour</surname><given-names>S.M.</given-names></name>
<name><surname>Ammar</surname><given-names>H.O.</given-names></name>
<name><surname>Ghorab</surname><given-names>M.M.</given-names></name>
<name><surname>Chougule</surname><given-names>M.B.</given-names></name>
<name><surname>Chablani</surname><given-names>L.</given-names></name>
</person-group><article-title>Design and evaluation of novel inhalable sildenafil citrate spray-dried microparticles for pulmonary arterial hypertension</article-title><source>J. Control. Release</source><year>2019</year><volume>302</volume><fpage>126</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.03.029</pub-id><pub-id pub-id-type="pmid">30940497</pub-id>
</element-citation></ref><ref id="B80-pharmaceutics-17-00224"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shahin</surname><given-names>H.</given-names></name>
<name><surname>Vinjamuri</surname><given-names>B.P.</given-names></name>
<name><surname>Mahmoud</surname><given-names>A.A.</given-names></name>
<name><surname>Mansour</surname><given-names>S.M.</given-names></name>
<name><surname>Chougule</surname><given-names>M.B.</given-names></name>
<name><surname>Chablani</surname><given-names>L.</given-names></name>
</person-group><article-title>Formulation and optimization of sildenafil citrate-loaded PLGA large porous microparticles using spray freeze-drying technique: A factorial design and in-vivo pharmacokinetic study</article-title><source>Int. J. Pharm.</source><year>2021</year><volume>597</volume><fpage>120320</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120320</pub-id><pub-id pub-id-type="pmid">33539999</pub-id>
</element-citation></ref><ref id="B81-pharmaceutics-17-00224"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>H.</given-names></name>
<name><surname>Ji</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Qiao</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
</person-group><article-title>In vivo pharmacokinetics and in vitro release of imatinib mesylate-loaded liposomes for pulmonary delivery</article-title><source>Int. J. Nanomed.</source><year>2021</year><volume>16</volume><fpage>1221</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.2147/IJN.S294626</pub-id></element-citation></ref><ref id="B82-pharmaceutics-17-00224"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rashid</surname><given-names>J.</given-names></name>
<name><surname>Alobaida</surname><given-names>A.</given-names></name>
<name><surname>Al-Hilal</surname><given-names>T.A.</given-names></name>
<name><surname>Hammouda</surname><given-names>S.</given-names></name>
<name><surname>McMurtry</surname><given-names>I.F.</given-names></name>
<name><surname>Nozik-Grayck</surname><given-names>E.</given-names></name>
<name><surname>Stenmark</surname><given-names>K.R.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Repurposing rosiglitazone, a PPAR-&#x003b3; agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH</article-title><source>J. Control. Release</source><year>2018</year><volume>280</volume><fpage>113</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.04.049</pub-id><pub-id pub-id-type="pmid">29723610</pub-id>
</element-citation></ref><ref id="B83-pharmaceutics-17-00224"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>V.</given-names></name>
<name><surname>Rawat</surname><given-names>A.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension</article-title><source>J. Pharm. Sci.</source><year>2010</year><volume>99</volume><fpage>1774</fpage><lpage>1789</lpage><pub-id pub-id-type="doi">10.1002/jps.21946</pub-id><pub-id pub-id-type="pmid">19894275</pub-id>
</element-citation></ref><ref id="B84-pharmaceutics-17-00224"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>V.</given-names></name>
<name><surname>Davis</surname><given-names>M.</given-names></name>
<name><surname>Hope-Weeks</surname><given-names>L.J.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>PLGA microparticles encapsulating prostaglandin E 1-hydroxypropyl-&#x003b2;-cyclodextrin (PGE 1-HP&#x003b2;CD) complex for the treatment of pulmonary arterial hypertension (PAH)</article-title><source>Pharm. Res.</source><year>2011</year><volume>28</volume><fpage>1733</fpage><lpage>1749</lpage><pub-id pub-id-type="doi">10.1007/s11095-011-0409-6</pub-id><pub-id pub-id-type="pmid">21626061</pub-id>
</element-citation></ref><ref id="B85-pharmaceutics-17-00224"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qi</surname><given-names>R.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Yan</surname><given-names>F.</given-names></name>
</person-group><article-title>Exosomes enriched by miR-429-3p derived from ITGB1 modified Telocytes alleviates hypoxia-induced pulmonary arterial hypertension through regulating Rac1 expression</article-title><source>Cell Biol. Toxicol.</source><year>2024</year><volume>40</volume><elocation-id>32</elocation-id><pub-id pub-id-type="doi">10.1007/s10565-024-09879-0</pub-id><pub-id pub-id-type="pmid">38767703</pub-id>
</element-citation></ref><ref id="B86-pharmaceutics-17-00224"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>N.</given-names></name>
<name><surname>Ibrahim</surname><given-names>H.M.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Peptide&#x02013;micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension</article-title><source>J. Pharm. Sci.</source><year>2014</year><volume>103</volume><fpage>3743</fpage><lpage>3753</lpage><pub-id pub-id-type="doi">10.1002/jps.24193</pub-id><pub-id pub-id-type="pmid">25266507</pub-id>
</element-citation></ref><ref id="B87-pharmaceutics-17-00224"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gupta</surname><given-names>N.</given-names></name>
<name><surname>Patel</surname><given-names>B.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Nano-engineered erythrocyte ghosts as inhalational carriers for delivery of fasudil: Preparation and characterization</article-title><source>Pharm. Res.</source><year>2014</year><volume>31</volume><fpage>1553</fpage><lpage>1565</lpage><pub-id pub-id-type="doi">10.1007/s11095-013-1261-7</pub-id><pub-id pub-id-type="pmid">24449438</pub-id>
</element-citation></ref><ref id="B88-pharmaceutics-17-00224"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nahar</surname><given-names>K.</given-names></name>
<name><surname>Absar</surname><given-names>S.</given-names></name>
<name><surname>Patel</surname><given-names>B.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Starch-coated magnetic liposomes as an inhalable carrier for accumulation of fasudil in the pulmonary vasculature</article-title><source>Int. J. Pharm.</source><year>2014</year><volume>464</volume><fpage>185</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.01.007</pub-id><pub-id pub-id-type="pmid">24463004</pub-id>
</element-citation></ref><ref id="B89-pharmaceutics-17-00224"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nahar</surname><given-names>K.</given-names></name>
<name><surname>Absar</surname><given-names>S.</given-names></name>
<name><surname>Gupta</surname><given-names>N.</given-names></name>
<name><surname>Kotamraju</surname><given-names>V.R.</given-names></name>
<name><surname>McMurtry</surname><given-names>I.F.</given-names></name>
<name><surname>Oka</surname><given-names>M.</given-names></name>
<name><surname>Komatsu</surname><given-names>M.</given-names></name>
<name><surname>Nozik-Grayck</surname><given-names>E.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Peptide-coated liposomal fasudil enhances site specific vasodilation in pulmonary arterial hypertension</article-title><source>Mol. Pharm.</source><year>2014</year><volume>11</volume><fpage>4374</fpage><lpage>4384</lpage><pub-id pub-id-type="doi">10.1021/mp500456k</pub-id><pub-id pub-id-type="pmid">25333706</pub-id>
</element-citation></ref><ref id="B90-pharmaceutics-17-00224"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rashid</surname><given-names>J.</given-names></name>
<name><surname>Nahar</surname><given-names>K.</given-names></name>
<name><surname>Raut</surname><given-names>S.</given-names></name>
<name><surname>Keshavarz</surname><given-names>A.</given-names></name>
<name><surname>Ahsan</surname><given-names>F.</given-names></name>
</person-group><article-title>Fasudil and DETA NONOate, loaded in a peptide-modified liposomal carrier, slow PAH progression upon pulmonary delivery</article-title><source>Mol. Pharm.</source><year>2018</year><volume>15</volume><fpage>1755</fpage><lpage>1765</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b01003</pub-id><pub-id pub-id-type="pmid">29528655</pub-id>
</element-citation></ref><ref id="B91-pharmaceutics-17-00224"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Qiao</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Ma</surname><given-names>M.</given-names></name>
<name><surname>Han</surname><given-names>X.</given-names></name>
<name><surname>Tang</surname><given-names>J.</given-names></name>
</person-group><article-title>DPPC-coated lipid nanoparticles as an inhalable carrier for accumulation of resveratrol in the pulmonary vasculature, a new strategy for pulmonary arterial hypertension treatment</article-title><source>Drug Deliv.</source><year>2020</year><volume>27</volume><fpage>736</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1080/10717544.2020.1760962</pub-id><pub-id pub-id-type="pmid">32397765</pub-id>
</element-citation></ref><ref id="B92-pharmaceutics-17-00224"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>C.-K.</given-names></name>
<name><surname>Zhen</surname><given-names>Y.-Y.</given-names></name>
<name><surname>Lu</surname><given-names>H.-I.</given-names></name>
<name><surname>Sung</surname><given-names>P.-H.</given-names></name>
<name><surname>Chang</surname><given-names>L.-T.</given-names></name>
<name><surname>Tsai</surname><given-names>T.-H.</given-names></name>
<name><surname>Sheu</surname><given-names>J.-J.</given-names></name>
<name><surname>Chen</surname><given-names>Y.-L.</given-names></name>
<name><surname>Chua</surname><given-names>S.</given-names></name>
<name><surname>Chang</surname><given-names>H.-W.</given-names></name>
</person-group><article-title>Reducing TRPC1 Expression through Liposome-Mediated siRNA Delivery Markedly Attenuates Hypoxia-Induced Pulmonary Arterial Hypertension in a Murine Model</article-title><source>Stem Cells Int.</source><year>2014</year><volume>2014</volume><fpage>316214</fpage><pub-id pub-id-type="doi">10.1155/2014/316214</pub-id><pub-id pub-id-type="pmid">25587286</pub-id>
</element-citation></ref><ref id="B93-pharmaceutics-17-00224"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guarino</surname><given-names>V.A.</given-names></name>
<name><surname>Wertheim</surname><given-names>B.M.</given-names></name>
<name><surname>Xiao</surname><given-names>W.</given-names></name>
<name><surname>Loscalzo</surname><given-names>J.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.Y.</given-names></name>
</person-group><article-title>Nanoparticle delivery of VEGF and SDF-1&#x003b1; as an approach for treatment of pulmonary arterial hypertension</article-title><source>Pulm. Circ.</source><year>2024</year><volume>14</volume><fpage>e12412</fpage><pub-id pub-id-type="doi">10.1002/pul2.12412</pub-id><pub-id pub-id-type="pmid">39380978</pub-id>
</element-citation></ref><ref id="B94-pharmaceutics-17-00224"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sorino</surname><given-names>C.</given-names></name>
<name><surname>Negri</surname><given-names>S.</given-names></name>
<name><surname>Spanevello</surname><given-names>A.</given-names></name>
<name><surname>Visca</surname><given-names>D.</given-names></name>
<name><surname>Scichilone</surname><given-names>N.</given-names></name>
</person-group><article-title>Inhalation therapy devices for the treatment of obstructive lung diseases: The history of inhalers towards the ideal inhaler</article-title><source>Eur. J. Intern Med.</source><year>2020</year><volume>75</volume><fpage>15</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.ejim.2020.02.023</pub-id><pub-id pub-id-type="pmid">32113944</pub-id>
</element-citation></ref><ref id="B95-pharmaceutics-17-00224"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mehta</surname><given-names>P.P.</given-names></name>
<name><surname>Ghoshal</surname><given-names>D.</given-names></name>
<name><surname>Pawar</surname><given-names>A.P.</given-names></name>
<name><surname>Kadam</surname><given-names>S.S.</given-names></name>
<name><surname>Dhapte-Pawar</surname><given-names>V.S.</given-names></name>
</person-group><article-title>Recent advances in inhalable liposomes for treatment of pulmonary diseases: Concept to clinical stance</article-title><source>J. Drug Deliv. Sci. Technol.</source><year>2020</year><volume>56</volume><fpage>101509</fpage><pub-id pub-id-type="doi">10.1016/j.jddst.2020.101509</pub-id></element-citation></ref><ref id="B96-pharmaceutics-17-00224"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ong</surname><given-names>H.X.</given-names></name>
<name><surname>Traini</surname><given-names>D.</given-names></name>
<name><surname>Young</surname><given-names>P.M.</given-names></name>
</person-group><article-title>Liposomes for Inhalation</article-title><source>J. Aerosol. Med. Pulm. Drug Deliv.</source><year>2024</year><volume>37</volume><fpage>100</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1089/jamp.2024.29112.hxo</pub-id><pub-id pub-id-type="pmid">38640446</pub-id>
</element-citation></ref><ref id="B97-pharmaceutics-17-00224"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zangiabadian</surname><given-names>M.</given-names></name>
<name><surname>Malekshahian</surname><given-names>D.</given-names></name>
<name><surname>Arabpour</surname><given-names>E.</given-names></name>
<name><surname>Abadi</surname><given-names>S.S.D.</given-names></name>
<name><surname>Yazarlou</surname><given-names>F.</given-names></name>
<name><surname>Bostanghadiri</surname><given-names>N.</given-names></name>
<name><surname>Centis</surname><given-names>R.</given-names></name>
<name><surname>Aghababa</surname><given-names>A.A.</given-names></name>
<name><surname>Farahbakhsh</surname><given-names>M.</given-names></name>
<name><surname>Nasiri</surname><given-names>M.J.</given-names></name>
<etal/>
</person-group><article-title>Amikacin liposome and Mycobacterium avium complex: A systematic review</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><elocation-id>e0279714</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0279714</pub-id><pub-id pub-id-type="pmid">36574432</pub-id>
</element-citation></ref><ref id="B98-pharmaceutics-17-00224"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Encinas-Basurto</surname><given-names>D.</given-names></name>
<name><surname>Eedara</surname><given-names>B.B.</given-names></name>
<name><surname>Mansour</surname><given-names>H.M.</given-names></name>
</person-group><article-title>Biocompatible biodegradable polymeric nanocarriers in dry powder inhalers (DPIs) for pulmonary inhalation delivery</article-title><source>J. Pharm. Investig.</source><year>2024</year><volume>54</volume><fpage>145</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1007/s40005-024-00671-0</pub-id></element-citation></ref><ref id="B99-pharmaceutics-17-00224"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zendehdel Baher</surname><given-names>S.</given-names></name>
<name><surname>Yaqoubi</surname><given-names>S.</given-names></name>
<name><surname>Asare-Addo</surname><given-names>K.</given-names></name>
<name><surname>Hamishehkar</surname><given-names>H.</given-names></name>
<name><surname>Nokhodchi</surname><given-names>A.</given-names></name>
</person-group><article-title>Dry Powder Formulation of Simvastatin Nanoparticles for Potential Application in Pulmonary Arterial Hypertension</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><elocation-id>895</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics14050895</pub-id><pub-id pub-id-type="pmid">35631481</pub-id>
</element-citation></ref><ref id="B100-pharmaceutics-17-00224"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paranjpe</surname><given-names>M.</given-names></name>
<name><surname>Finke</surname><given-names>J.H.</given-names></name>
<name><surname>Richter</surname><given-names>C.</given-names></name>
<name><surname>Gothsch</surname><given-names>T.</given-names></name>
<name><surname>Kwade</surname><given-names>A.</given-names></name>
<name><surname>B&#x000fc;ttgenbach</surname><given-names>S.</given-names></name>
<name><surname>M&#x000fc;ller-Goymann</surname><given-names>C.C.</given-names></name>
</person-group><article-title>Physicochemical characterization of sildenafil-loaded solid lipid nanoparticle dispersions (SLN) for pulmonary application</article-title><source>Int. J. Pharm.</source><year>2014</year><volume>476</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2014.09.031</pub-id><pub-id pub-id-type="pmid">25261709</pub-id>
</element-citation></ref><ref id="B101-pharmaceutics-17-00224"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Shi</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>T.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Qiu</surname><given-names>S.</given-names></name>
<name><surname>Ruiz</surname><given-names>M.</given-names></name>
<name><surname>Dupuis</surname><given-names>J.</given-names></name>
<name><surname>Zhu</surname><given-names>L.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>Au-modified ceria nanozyme prevents and treats hypoxia-induced pulmonary hypertension with greatly improved enzymatic activity and safety</article-title><source>J. Nanobiotechnol.</source><year>2024</year><volume>22</volume><elocation-id>492</elocation-id><pub-id pub-id-type="doi">10.1186/s12951-024-02738-4</pub-id></element-citation></ref><ref id="B102-pharmaceutics-17-00224"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Cuddigan</surname><given-names>J.L.</given-names></name>
<name><surname>Gupta</surname><given-names>S.K.</given-names></name>
<name><surname>Meenach</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Nanocomposite microparticles (nCmP) for the delivery of tacrolimus in the treatment of pulmonary arterial hypertension</article-title><source>Int. J. Pharm.</source><year>2016</year><volume>512</volume><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2016.08.047</pub-id><pub-id pub-id-type="pmid">27568494</pub-id>
</element-citation></ref><ref id="B103-pharmaceutics-17-00224"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Teymouri Rad</surname><given-names>R.</given-names></name>
<name><surname>Dadashzadeh</surname><given-names>S.</given-names></name>
<name><surname>Vatanara</surname><given-names>A.</given-names></name>
<name><surname>Alavi</surname><given-names>S.</given-names></name>
<name><surname>Ghasemian</surname><given-names>E.</given-names></name>
<name><surname>Mortazavi</surname><given-names>S.A.</given-names></name>
</person-group><article-title>Tadalafil nanocomposites as a dry powder formulation for inhalation, a new strategy for pulmonary arterial hypertension treatment</article-title><source>Eur. J. Pharm. Sci.</source><year>2019</year><volume>133</volume><fpage>275</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.ejps.2019.04.001</pub-id><pub-id pub-id-type="pmid">30953751</pub-id>
</element-citation></ref><ref id="B104-pharmaceutics-17-00224"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Honmane</surname><given-names>S.</given-names></name>
<name><surname>Hajare</surname><given-names>A.</given-names></name>
<name><surname>More</surname><given-names>H.</given-names></name>
<name><surname>Osmani</surname><given-names>R.A.M.</given-names></name>
<name><surname>Salunkhe</surname><given-names>S.</given-names></name>
</person-group><article-title>Lung delivery of nanoliposomal salbutamol sulfate dry powder inhalation for facilitated asthma therapy</article-title><source>J. Liposome Res.</source><year>2019</year><volume>29</volume><fpage>332</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1080/08982104.2018.1531022</pub-id><pub-id pub-id-type="pmid">30296863</pub-id>
</element-citation></ref><ref id="B105-pharmaceutics-17-00224"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Leal</surname><given-names>J.</given-names></name>
<name><surname>Soto</surname><given-names>M.R.</given-names></name>
<name><surname>Smyth</surname><given-names>H.D.C.</given-names></name>
<name><surname>Ghosh</surname><given-names>D.</given-names></name>
</person-group><article-title>Aerosolizable Lipid Nanoparticles for Pulmonary Delivery of mRNA through Design of Experiments</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>1042</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12111042</pub-id><pub-id pub-id-type="pmid">33143328</pub-id>
</element-citation></ref><ref id="B106-pharmaceutics-17-00224"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wei</surname><given-names>Y.</given-names></name>
<name><surname>Zhao</surname><given-names>L.</given-names></name>
</person-group><article-title>Passive lung-targeted drug delivery systems via intravenous administration</article-title><source>Pharm. Dev. Technol.</source><year>2014</year><volume>19</volume><fpage>129</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.3109/10837450.2012.757782</pub-id><pub-id pub-id-type="pmid">23336716</pub-id>
</element-citation></ref><ref id="B107-pharmaceutics-17-00224"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yin</surname><given-names>Y.</given-names></name>
<name><surname>Wu</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>Z.</given-names></name>
<name><surname>Zhao</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Yuan</surname><given-names>M.</given-names></name>
<name><surname>Xie</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>He</surname><given-names>Q.</given-names></name>
</person-group><article-title>The Potential Efficacy of R8-Modified Paclitaxel-Loaded Liposomes on Pulmonary Arterial Hypertension</article-title><source>Pharm. Res.</source><year>2013</year><volume>30</volume><fpage>2050</fpage><lpage>2062</lpage><pub-id pub-id-type="doi">10.1007/s11095-013-1058-8</pub-id><pub-id pub-id-type="pmid">23756757</pub-id>
</element-citation></ref><ref id="B108-pharmaceutics-17-00224"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>M.</given-names></name>
<name><surname>Shang</surname><given-names>X.</given-names></name>
<name><surname>Lou</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Xiang</surname><given-names>S.</given-names></name>
<name><surname>Qiu</surname><given-names>Y.</given-names></name>
<name><surname>Hu</surname><given-names>F.</given-names></name>
<name><surname>Yu</surname><given-names>F.</given-names></name>
<name><surname>Yuan</surname><given-names>H.</given-names></name>
</person-group><article-title>Active Anchoring Stimuli-Responsive Nano-Craft to Relieve Pulmonary Vasoconstriction by Targeting Smooth Muscle Cell for Hypoxic Pulmonary Hypertension Treatment</article-title><source>Adv. Healthc. Mater.</source><year>2024</year><volume>13</volume><fpage>2400113</fpage><pub-id pub-id-type="doi">10.1002/adhm.202400113</pub-id></element-citation></ref><ref id="B109-pharmaceutics-17-00224"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dunn</surname><given-names>A.W.</given-names></name>
<name><surname>Kalinichenko</surname><given-names>V.V.</given-names></name>
<name><surname>Shi</surname><given-names>D.</given-names></name>
</person-group><article-title>Highly Efficient In Vivo Targeting of the Pulmonary Endothelium Using Novel Modifications of Polyethylenimine: An Importance of Charge</article-title><source>Adv. Healthc. Mater.</source><year>2018</year><volume>7</volume><fpage>1800876</fpage><pub-id pub-id-type="doi">10.1002/adhm.201800876</pub-id><pub-id pub-id-type="pmid">30398703</pub-id>
</element-citation></ref><ref id="B110-pharmaceutics-17-00224"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lai</surname><given-names>Y.-J.</given-names></name>
<name><surname>Hsu</surname><given-names>H.-H.</given-names></name>
<name><surname>Chang</surname><given-names>G.-J.</given-names></name>
<name><surname>Lin</surname><given-names>S.-H.</given-names></name>
<name><surname>Chen</surname><given-names>W.-J.</given-names></name>
<name><surname>Huang</surname><given-names>C.-C.</given-names></name>
<name><surname>Pang</surname><given-names>J.-H.S.</given-names></name>
</person-group><article-title>Prostaglandin E1 Attenuates Pulmonary Artery Remodeling by Activating Phosphorylation of CREB and the PTEN Signaling Pathway</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>9974</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-09707-y</pub-id><pub-id pub-id-type="pmid">28855544</pub-id>
</element-citation></ref><ref id="B111-pharmaceutics-17-00224"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Parayath</surname><given-names>N.N.</given-names></name>
<name><surname>Parikh</surname><given-names>A.</given-names></name>
<name><surname>Amiji</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Repolarization of Tumor-Associated Macrophages in a Genetically Engineered Nonsmall Cell Lung Cancer Model by Intraperitoneal Administration of Hyaluronic Acid-Based Nanoparticles Encapsulating MicroRNA-125b</article-title><source>Nano Lett.</source><year>2018</year><volume>18</volume><fpage>3571</fpage><lpage>3579</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.8b00689</pub-id><pub-id pub-id-type="pmid">29722542</pub-id>
</element-citation></ref><ref id="B112-pharmaceutics-17-00224"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shewale</surname><given-names>H.</given-names></name>
<name><surname>Kanugo</surname><given-names>A.</given-names></name>
</person-group><article-title>Formulation Optimization and Evaluation of Patented Solid Lipid Nanoparticles of Ambrisentan for Pulmonary Arterial Hypertension</article-title><source>Recent Pat. Nanotechnol.</source><year>2024</year><comment>
<italic toggle="yes">in press</italic>
</comment><pub-id pub-id-type="doi">10.2174/0118722105302631240816115638</pub-id><pub-id pub-id-type="pmid">39354770</pub-id>
</element-citation></ref><ref id="B113-pharmaceutics-17-00224"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Q.Q.</given-names></name>
<name><surname>Jing</surname><given-names>Z.C.</given-names></name>
</person-group><article-title>The limits of oral therapy in pulmonary arterial hypertension management</article-title><source>Ther. Clin. Risk Manag.</source><year>2015</year><volume>11</volume><fpage>1731</fpage><lpage>1741</lpage><pub-id pub-id-type="doi">10.2147/tcrm.S49026</pub-id><pub-id pub-id-type="pmid">26648729</pub-id>
</element-citation></ref><ref id="B114-pharmaceutics-17-00224"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abrahim-Vieira</surname><given-names>B.A.</given-names></name>
<name><surname>Souza</surname><given-names>A.M.T.</given-names></name>
<name><surname>Barros</surname><given-names>R.C.</given-names></name>
<name><surname>Carmo</surname><given-names>F.A.D.</given-names></name>
<name><surname>Abreu</surname><given-names>L.C.L.</given-names></name>
<name><surname>Moreira</surname><given-names>R.S.S.</given-names></name>
<name><surname>Hon&#x000d3;rio</surname><given-names>T.S.</given-names></name>
<name><surname>Rodrigues</surname><given-names>C.R.</given-names></name>
<name><surname>Sousa</surname><given-names>V.P.</given-names></name>
<name><surname>Cabral</surname><given-names>L.M.</given-names></name>
</person-group><article-title>In Silico studies of novel Sildenafil self-emulsifying drug delivery system absorption improvement for pulmonary arterial hypertension</article-title><source>An. Acad. Bras. Ci&#x000ea;ncias</source><year>2020</year><volume>92</volume><fpage>e20191445</fpage><pub-id pub-id-type="doi">10.1590/0001-3765202020191445</pub-id><pub-id pub-id-type="pmid">32785428</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceutics-17-00224-f001"><label>Figure 1</label><caption><p>Schematic representation of a nanocarrier-based approach targeting the fundamental causes of PAH. The diagram illustrates the pathological changes in the pulmonary artery of PAH patients and highlights the mechanism of nanocarrier-mediated delivery to pulmonary arterial endothelial cells and pulmonary arterial smooth muscle cells. Created in BioRender. Jisu, P. (2025) <uri xlink:href="https://BioRender.com/y93a096">https://BioRender.com/y93a096</uri>, accessed on 30 December 2024.</p></caption><graphic xlink:href="pharmaceutics-17-00224-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00224-f002"><label>Figure 2</label><caption><p>Routes of Pulmonary Drug Delivery. Illustration of pulmonary drug delivery methods, including nebulization, dry powder inhalers (DPI) or metered dose inhalers (MDI), and infusion. These delivery routes highlight the variety of strategies employed for effective pulmonary administration. Created in BioRender. Jisu, P. (2025) <uri xlink:href="https://BioRender.com/y93a096">https://BioRender.com/y93a096</uri>.</p></caption><graphic xlink:href="pharmaceutics-17-00224-g002" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00224-t001"><object-id pub-id-type="pii">pharmaceutics-17-00224-t001_Table 1</object-id><label>Table 1</label><caption><p>Approved drugs for PAH treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug Class</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Drug</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mode of Action</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Endothelin receptor antagonists</td><td align="left" valign="middle" rowspan="1" colspan="1">Bosentan <break/>monohydrate</td><td align="left" valign="middle" rowspan="1" colspan="1">Reduces the pathogenic effects of elevated endothelin-1 in PAH</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">Macitentan</td><td align="left" valign="middle" rowspan="1" colspan="1">Reduces vasoconstriction and smooth muscle cell proliferation in pulmonary arteries</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">Ambrisentan</td><td align="left" valign="middle" rowspan="1" colspan="1">Inhibits vasoconstriction and cell proliferation while preserving ETB receptor-mediated vasodilation and ET-1 clearance</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PDE5 inhibitor</td><td align="left" valign="middle" rowspan="1" colspan="1">Sildenafil<break/>citrate</td><td align="left" valign="middle" rowspan="1" colspan="1">Increases cGMP levels in pulmonary vascular smooth muscle cells, inducing vasodilation of the pulmonary vascular bed</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">Tadalafil</td><td align="left" valign="middle" rowspan="1" colspan="1">Increases cGMP levels to enhance smooth muscle relaxation, reducing pulmonary arterial pressure and vascular remodeling in PAH</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">Vardenafil <break/>hydrochloride</td><td align="left" valign="middle" rowspan="1" colspan="1">Increases cGMP levels to promote smooth muscle relaxation and vasodilation in the pulmonary vasculature in PAH</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Prostacyclin analog</td><td align="left" valign="middle" rowspan="1" colspan="1">Epoprostenol sodium</td><td align="left" valign="middle" rowspan="1" colspan="1">Activates G protein-coupled receptors to increase cAMP, inhibiting platelet aggregation and inducing vasodilation</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">Iloprost <break/>tromethamine</td><td align="left" valign="middle" rowspan="1" colspan="1">Mimics prostacyclin to induce vasodilation, reduce oxidative stress, and protect endothelial and mitochondrial function in PAH</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
</td><td align="left" valign="middle" rowspan="1" colspan="1">Treprostinil</td><td align="left" valign="middle" rowspan="1" colspan="1">Activates prostacyclin receptors to increase cAMP, inducing vasodilation, inhibiting platelet aggregation, and reducing inflammation in PAH</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Selective IP receptor agonist</td><td align="left" valign="middle" rowspan="1" colspan="1">Selexipag</td><td align="left" valign="middle" rowspan="1" colspan="1">Promotes vasodilation, inhibits vascular smooth muscle proliferation, and reduces inflammation in PAH</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Soluble guanylate cyclase stimulator</td><td align="left" valign="middle" rowspan="1" colspan="1">Riociguat</td><td align="left" valign="middle" rowspan="1" colspan="1">Increases cGMP generation to enhance vasodilation and reduce vascular remodeling in PAH</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activin receptor type IIA-Fc fusion protein</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sotatercept</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acts as a ligand trap for activin-class ligands to restore BMP signaling and reduce pulmonary vascular remodeling in PAH</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00224-t002"><object-id pub-id-type="pii">pharmaceutics-17-00224-t002_Table 2</object-id><label>Table 2</label><caption><p>Nanocarrier-based pulmonary targeted strategies for PAH treatment.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapeutic Cargo</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Therapeutic Strategy</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Core Materials for Carriers</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Route</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Animal Model</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BMPR2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SIN3a gene</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increase BMPR2 expression in the epigenetic pathway to overcome BMPR2 silencing caused by methylation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adeno-associated virus serotype1 (AAV1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal (aerosol inhalation)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-pharmaceutics-17-00224" ref-type="bibr">69</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BOLA3</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BOLA3 gene</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Induce the expression of BOLA3, which plays a key role in PH pathogenesis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lentiviral vector</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Orotracheal instillation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-pharmaceutics-17-00224" ref-type="bibr">70</xref>]</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Endothelin receptor</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ambrisentan</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevent or reverse histological change caused by elevated levels of ET1, treatment of PAH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n.a.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-pharmaceutics-17-00224" ref-type="bibr">71</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ambrisentan, NaNO2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Block the vasoconstrictive response in blood vessels, act as a pulmonary vasodilator</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Perfluorooctyl bromide emulsion</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-pharmaceutics-17-00224" ref-type="bibr">72</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bosentan</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevent or reverse histological change caused by elevated levels of ET1, treatment of PAH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Wistar Albino rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-pharmaceutics-17-00224" ref-type="bibr">27</xref>]</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Guanylate cyclase</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diethylenetriamine NONOate</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activate guanylate cyclase to produces vasodilation and reduce smooth muscle cell proliferation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposome (PEGylated)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B73-pharmaceutics-17-00224" ref-type="bibr">73</xref>] </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cinaciguat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Activate soluble guanylate cyclase (increase vasodilation of pulmonary arteries), decrease pulmonary arterial blood pressure</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA, polyvinyl pyrrolidone (PVP)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal (dry powder insufflator)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat, Mini-Pig</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B74-pharmaceutics-17-00224" ref-type="bibr">74</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HMG-CoA reductase</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cerivastatin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit smooth muscle cell proliferation, improve endothelial function, reduce inflammation and oxidative stress</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhalation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-pharmaceutics-17-00224" ref-type="bibr">75</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I&#x003ba;B</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H2S-releasing asprin derivative (ACS14)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit the EndMT process by suppressing I&#x003ba;B degradation and NF-&#x003ba;B activation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B76-pharmaceutics-17-00224" ref-type="bibr">76</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pdgfb</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pdgfb siRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prevent hypoxia-induced distal pulmonary arteriole muscularization, PH, and RVH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PPMS </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Orotracheal instillation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B77-pharmaceutics-17-00224" ref-type="bibr">77</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nuclear factor &#x003ba;B</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decoy oligonucleotide</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Attenuate inflammation, proliferation, development of PAH and pulmonary arterial remodeling</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal instillation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B78-pharmaceutics-17-00224" ref-type="bibr">78</xref>]</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">PDE5</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tadalafil</td><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Increase level of cGMP and nitric oxide in pulmonary vasculature to reduce pulmonary arterial pressure</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoemulsion</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Orotracheal instillation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B36-pharmaceutics-17-00224" ref-type="bibr">36</xref>] </td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Sildenafil</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B31-pharmaceutics-17-00224" ref-type="bibr">31</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Carboxymethyl cellulose/sodium alginate hydrogel microparticle</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Albino rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B79-pharmaceutics-17-00224" ref-type="bibr">79</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Albino rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B80-pharmaceutics-17-00224" ref-type="bibr">80</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PDE5, PPAR-&#x003b3;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sildenafil, Rosiglitazone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increase level of cGMP and nitric oxide in pulmonary vasculature to reduce pulmonary arterial pressure. inhibit PASMC proliferation by modulating cell growth and apoptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B56-pharmaceutics-17-00224" ref-type="bibr">56</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PDGF-receptor tyrosine kinase</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Imatinib</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reverse pulmonary vascular remodeling, anti-proliferative and pro-apoptotic effects</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B81-pharmaceutics-17-00224" ref-type="bibr">81</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PPAR-&#x003b3;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rosiglitazone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit PASMC proliferation by modulating cell growth and apoptosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B82-pharmaceutics-17-00224" ref-type="bibr">82</xref>]</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Prostaglandin E receptors</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Prostaglandin E1</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Vasodilatory, anti-inflammatory, anti-aggregatory, and anti-proliferative properties</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal (aerosol inhalation)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B83-pharmaceutics-17-00224" ref-type="bibr">83</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B84-pharmaceutics-17-00224" ref-type="bibr">84</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rac1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">miR-429-3p</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inhibit proliferation and migration of PASMCs, vascular remodeling of pulmonary arterial walls observed in PAH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Exosomes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B85-pharmaceutics-17-00224" ref-type="bibr">85</xref>]</td></tr><tr><td rowspan="9" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Rho-kinase</td><td rowspan="8" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Fasudil</td><td rowspan="9" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Dilate pulmonary arteries and arterioles, reduces arterial remodeling, prolonged pulmonary preferential vasodilation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B48-pharmaceutics-17-00224" ref-type="bibr">48</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Peptide&#x02013;micelle hybrid particle</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B86-pharmaceutics-17-00224" ref-type="bibr">86</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoerythrosomes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B87-pharmaceutics-17-00224" ref-type="bibr">87</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Starch-coated magnetic liposomes (PEGylated)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B88-pharmaceutics-17-00224" ref-type="bibr">88</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nanoerythrosomes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B62-pharmaceutics-17-00224" ref-type="bibr">62</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposome (PEGylated)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B89-pharmaceutics-17-00224" ref-type="bibr">89</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAR-liposomes (PEGylated)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B90-pharmaceutics-17-00224" ref-type="bibr">90</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposome (PEGylated)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal, intravenous</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B60-pharmaceutics-17-00224" ref-type="bibr">60</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fasudil, SOD</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposome (PEGylated)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B61-pharmaceutics-17-00224" ref-type="bibr">61</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ROS, HMGB1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ethyl pyruvate </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased levels of HMGB1, IL-6, TNF&#x003b1;, reactive oxygen species, and ET1 in lung improve pulmonary arterial remodeling</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG-PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-pharmaceutics-17-00224" ref-type="bibr">51</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SIRT1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Resveratrol</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Increased PASMC apoptosis to attenuate pulmonary arterial remodeling and the alleviation of PAH</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid nanoparticles</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B91-pharmaceutics-17-00224" ref-type="bibr">91</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPC1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TRPC1 siRNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Attenuate PAH-associated RV and pulmonary arteriolar remodeling</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B92-pharmaceutics-17-00224" ref-type="bibr">92</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEGFR2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEGF, SDF</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Block VEGF signaling to facilitate utilizing extra-pulmonary progenitor cells for pulmonary endothelial repair and delayed the thickening of distal pulmonary vessels</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chitosan</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intratracheal (aerosol inhalation)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Athymic nude rat, Sprague&#x02013;Dawley rat</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-pharmaceutics-17-00224" ref-type="bibr">93</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>BMPR2, bone morphogenetic protein receptor type 2; PDE5, phosphodiesterase type 5; Pdgfb, platelet-derived growth factor B; PEG-PLGA, poly-(ethylene glycol)-block-lactide/glycolide copolymer; PLGA, poly(lactic-co-glycolic acid); PPAR-&#x003b3;, peroxisome-proliferator-activated-receptor-gamma; PPMS, poly(pentadecalactone-co-n-methyldiethanolamineco-sebacate); SDF, stromal cell-derived factor-1&#x003b1;; SIRT1, silence information regulator 1; SOD, superoxide dismutase; TRPC1, transient receptor potential cation channel 1; VEGF, vascular endothelial growth factor.</p></fn></table-wrap-foot></table-wrap></floats-group></article>